Awareness of cognitive abilities in people with Parkinson's disease by McKie, Kaye
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
n  
 
 
 
 
 
McKie, Kaye (2015) Awareness of cognitive abilities in people with 
Parkinson's disease. D Clin Psy thesis. 
 
http://theses.gla.ac.uk/6765/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
DClinPsy 2015 University of Glasgow 
Page | 1 
 
  
Awareness of Cognitive Abilities in People with 
Parkinson’s Disease  
And Clinical Research Portfolio 
Volume 1  
(Volume 2 bound separately) 
 
Kaye McKie, MA (Hons) 
 
Submitted in partial fulfilment of the requirements for the degree of  
Doctorate in Clinical Psychology 
 
Institute of Health and Wellbeing 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
October 2015  
  
  
 
DClinPsy 2015 University of Glasgow 
Page | 2 
 
 
Declaration of Originality Form  
This form must be completed and signed and submitted with all assignments. 
Please complete the information below (using BLOCK CAPITALS). 
Name:  KAYE MCKIE 
Student Number: 2058484M 
Course Name:   DOCTORATE IN CLINICAL PSYCHOLOGY  
Assignment Number/Name: CLINICAL RESEARCH PORTFOLIO 
An extract from the University’s Statement on Plagiarism is provided overleaf.  Please 
read carefully THEN read and sign the declaration below. 
I confirm that this assignment is my own work and that I have: 
Read and understood the guidance on plagiarism in the Doctorate in Clinical Psychology 
Programme Handbook, including the University of Glasgow Statement on Plagiarism 
 
Clearly referenced, in both the text and the bibliography or references, all sources used in 
the work  
 
Fully referenced (including page numbers) and used inverted commas for all text quoted 
from books, journals, web etc. (Please check the section on referencing in the ‘Guide to 
Writing Essays & Reports’ appendix of the Graduate School Research Training 
Programme handbook.) 
 
Provided the sources for all tables, figures, data etc. that are not my own work  
Not made use of the work of any other student(s) past or present without 
acknowledgement.  This includes any of my own work, that has been previously, or 
concurrently, submitted for assessment, either at this or any other educational institution, 
including school (see overleaf at 31.2) 
 
Not sought or used the services of any professional agencies to produce this work  
In addition, I understand that any false claim in respect of this work will result in 
disciplinary action in accordance with University regulations 
 
DECLARATION: 
I am aware of and understand the University’s policy on plagiarism and I certify that this 
assignment is my own work, except where indicated by referencing, and that I have 
followed the good academic practices noted above 
Signature                                                                                                               Date 
 
DClinPsy 2015 University of Glasgow 
Page | 3 
 
 
Acknowledgements  
Firstly, I would like to thank my supervisors, Dr Hamish McLeod and Dr Jim Law for 
their continual support and guidance throughout this project. Thank you for the 
exceptional learning experience you have provided me with, it has been a pleasure to 
work alongside such dedicated and inspiring individuals. 
 
I am thankful to the Parkinson’s disease Team for their vested interest in this research. I 
am extremely grateful to Sharon Sutherland, your sheer determination with recruitment 
made this project possible. I would like to extend my sincerest thanks to all of the 
participants who freely gave their time to take part in this research, without them this 
project would not have been possible.  
 
I sincerely thank NHS Education for Scotland and the University of Glasgow for 
providing me with this training opportunity. I am especially thankful to NHS Highland 
and my placement supervisors who have provided unwavering support throughout my 
training, it has been a privilege to work with you. 
 
Most importantly, I want to thank my family. Thank you Mum and Dad for your 
continual support and belief in me. Thank you to my sisters, Kirstie and Morag for 
providing me with humour and welcome distractions. Lastly, I want to thank Allan for 
his never ending support and encouragement over the last three years.  
 
 
 
 
 
 
DClinPsy 2015 University of Glasgow 
Page | 4 
 
 
Table of Contents 
 
Volume One                     Page         
 
Chapter 1  -  Systematic Review        6 
A Systematic Review of Factors Associated with Depression and Awareness  
in People with Parkinson’s Disease. 
 
Chapter 2  -  Major Research Project       52 
Unawareness of Cognitive Abilities in People with Parkinson’s Disease:  
A Case-Controlled Study. 
 
Chapter 3  -  Advanced Clinical Practice I Reflective Account   95 
(Abstract Only)        
My Clinical Psychology journey; ‘naïve undergraduate to competent clinician’.  
A reflective account of my personal and professional development in clinical practice. 
 
Chapter 4  -  Advanced Clinical Practice II Reflective Account     97 
(Abstract Only)      
Being a Scientist Practitioner is at the heart of every Clinical Psychologist.  
‘So What?’ 
    
Appendices:  Systematic Review       99
   
1.1 Journal Submission Details: Neuropsychological Rehabilitation   100 
Author Guidelines          
1.2 Data Extraction Sheet        102 
1.3 Quality Ratings for all Included Articles           108 
 
DClinPsy 2015 University of Glasgow 
Page | 5 
 
 
Appendices:   Major Research Project 
2.1 Journal Submission Details: Journal of Neurology, Neurosurgery  
and Psychiatry -  Author Guidelines      109 
2.2 Ethical Approval Letter I        113 
2:3 Ethical Approval Letter II        119 
2.4 Research and Development Approval Letter     123 
2.5 Participant Consent to Contact Form              125 
2.6 Participant Information Sheet              127 
2.7 Participant Consent Form               131 
2.8 Major Research Project Proposal            133 
2.9 Addendum to Major Research Project Proposal     147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DClinPsy 2015 University of Glasgow 
Page | 6 
 
 
 
 
 
 
Chapter 1: Systematic Review 
 
 
A Systematic Review of Factors Associated with Depression and 
Awareness 
in People with Parkinson’s Disease. 
 
 
Kaye McKie* 
 
 
 
Prepared in accordance with the instructions to authors for the Neuropsychological 
Rehabilitation: An International Journal (see Appendix 1.1) 
 
 
 
 
*Address for correspondence: 
Mental Health and Wellbeing  
Academic Centre  
Gartnavel Royal Hospital  
1055 Great Western Road  
Glasgow,  
G12 0XH  
Tel: 0141 211 3927 
 
 
 
DClinPsy 2015 University of Glasgow 
Page | 7 
 
 
 
 
Chapter 1  -  Systematic Review 
 A Systematic Review of Factors Associated with Depression and Awareness 
 in People with Parkinson’s Disease. 
 
Contents        Page 
 
Abstract……………………………………………………………....8 
Introduction………………………………………………………..…9 
Methods……………………………………………………………..14 
Results and Discussion……………………………………………...19 
Conclusion…………………………………………………………..40 
References…………………………………………………………...45 
 
 
 
 
 
 
 
 
 
 
 
 
DClinPsy 2015 University of Glasgow 
Page | 8 
 
 
Abstract 
Background: People with Parkinson’s disease (PD) are at an elevated risk of 
developing depression than the general population. Current literature suggests that there 
is a cross-over of phenomenology between these two conditions, however specific risk 
factors contributing to depression in PD remains unclear. Previous studies have also 
suggested that awareness of illness has an impact on emotional responses such as 
depression. However, the interaction between level of awareness and depression in PD 
has not been reviewed. Aim: To systematically review the evidence regarding risk 
factors for depression in PD and to examine the relationship between awareness and 
depression. Methods: A systematic literature search was conducted using Medline, 
Embase, Cinahl, Psychinfo and Psycharticles. Eligibility criteria were devised and 
included studies were assessed on methodological quality using the Crowe Critical 
Appraisal Tool (CCAT). Results: Nine articles met inclusion criteria. Four studies 
examined risk factors for depression in PD. Findings identified a total of 17 risk factors 
which were sub-typed into; clinical, motor, cognitive and physiological factors. The 
remaining five studies explored the association between awareness and depression. 
Results of these studies were mixed, with only two reporting a significant association 
between level of awareness and severity of depression. Conclusions: Data extracted 
highlighted that the majority of identified risk factors for depression were associated 
with PD symptoms. A relatively small evidence base exists in the association between 
awareness and severity of depressive symptoms in PD. Due to methodological factors 
such as utilized measures, limited conclusions were drawn from the findings of the 
included studies. Further high quality research is needed to clarify the relationship 
between awareness and depression in the PD population.  
 
Keywords: Parkinson’s disease, Depression, Awareness, Risk Factors 
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Introduction 
 
Parkinson’s disease (PD) is a neurodegenerative condition associated with a range of 
motor and cognitive symptoms (Peto, Jenkinson, Fitzpatrick & Greenhail, 1995; 
Muslimovic, Post, Speelman & Schmand, 2005). PD has a prevalence rate of 1 in 500, 
with an average age of onset around 60 years (Schrag and Schott, 2006). In addition to 
motor and cognitive symptoms, individuals with PD experience higher rates of 
depression than the general population. The estimated prevalence rate of depressive 
disorders in PD is approximately 40%, compared to 13.5% in the general population 
(Ishihara & Brayne, 2006; Schrag et al., 2007; Pachana et al., 2013). Despite the 
elevated risk of developing depression, fewer than 20% of depressed PD patients 
receive appropriate treatment (BPS, 2009).  Under-diagnosis may be due to factors such 
as methodological differences in diagnosing depression and clinical features of mood 
disorders overlapping with the motor and non-motor symptoms of PD (Pachana et al, 
2013).  
 
Many depressive symptoms and PD symptoms (e.g. fatigue) overlap. This cross-over of 
phenomenology between these two conditions presents PD individuals with a barrier to 
diagnosis.  Poewe (2008) stated that signs of depression may originate from the motor 
problems experienced by people with PD and not from mood. Gallagher, Lees, and 
Schrag (2010) suggested that individuals with PD without depression may also exhibit 
these ‘depressed’ symptoms due to their diagnosis of PD. This diagnostic 
overshadowing may also contribute to an under-diagnosis of depression in PD, due to 
similar characteristics of depression being wrongly diagnosed as part of motor problems 
(Fernandez, 2012).   
 
Theories of Depression in PD and Associated Risk Factors 
There are three competing theories of the association between PD and depression. 
Mayeux’s (1990) ‘serotonin hypothesis’ stated that depression was intrinsic to PD and a 
direct result of underlying neuropathological changes to brain structure and function. 
Alternatively, Tandberg, Larsen, Aarsland, Laake and Cummings (1997) suggested that  
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environmental, situational and psychological factors may contribute to mood changes in 
PD and proposed that depressive symptoms in PD represented an understandable 
reaction to the diagnosis of a progressive impairment. Recently, Negre-Pages et al., 
(2010) stated that no clear unidirectional relationships existed between either theory, 
and proposed that a combination of biological and psychosocial factors influenced 
mood and exacerbated PD symptomology. In summary, three pathways between 
depression and PD have been proposed; 1. All biological; 2. All adjustment reaction; or 
3. An interaction between biological and psychosocial factors. 
 
Previous studies have described correlates of depression commonly found in people 
with PD, such as level of education, with more educated patients less likely to be 
depressed (Dissanayaka, et al., 2011).  In their sample, depression was associated with 
younger age of onset, longer duration of PD, memory problems, hallucinations, sleep 
disturbances, postural hypotension and falls. Schrag, Jahanshahi and Quinn (2001) also 
suggested that impaired activities of daily living, high rates of apathy, PD severity and 
longer treatment duration were all associated with symptoms of depression. Sagna, 
Gallo and Pontone (2014) integrated these findings into a biopsychosocial framework in 
the development of depression in older adults with PD. This framework included 
sources of risk and resilience in PD patients; such as severity of motor symptoms, 
access to social support and family relationships, past psychiatric history, coping 
strategies and personality type.   
 
Current literature suggests that individuals with PD and depression present clinicians 
with a complex presentation of intertwining symptoms. Evidence has suggested that 
depressive symptoms occur more frequently in patients with PD than in the general 
population, however specific risk factors contributing to depression in PD remain 
unclear (Dissanayaka et al, 2011). Rickards (2006) systematic review into factors 
associated with depression and neurological conditions, including PD, stated that altered 
mental states are an intrinsic part of neurological disorders and may influence the way 
patients experience their illnesses. This concept of perception of disability, how aware  
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the individual with PD is of their PD symptoms has recently received research attention. 
Of particular interest in this current systematic review is the possible association 
between awareness and depression in PD. 
 
Awareness and Depression in Individuals with PD 
Recognition of one’s deficits varies along a continuum from complete unawareness 
(anosognosia) to full awareness (McGlynn & Schacter, 1989). Unawareness involves an 
inadequate evaluation of one’s impairments with individuals often underestimating or 
denying their deficits, whereas individuals who are said to be aware are able to detect 
the presence of impairments associated with their disability (Clare, 2004). Awareness 
may also be described as a lack of insight or judgement. The ability to be aware of 
illness and associated deficits, allows individuals to recognize being ill and to assign a 
correct meaning to the symptoms they experience (Orfei et al, 2008). The phenomenon 
of awareness can be thought of as arising from interactions between different 
neuropsychosocial determinants, such as the patient’s attitudes, beliefs, coping skills, 
and cultural social context (Halligan, 2006). Unawareness may originate from a 
person’s behavioural reaction to a diagnosis of a serious or life-changing illness. This 
reactive mechanism may take the form of a process of adjustment, adaptation and 
accommodation to the changing physical, social and psychological needs associated 
with a neurological condition (Hurwitz & Calne, 2001). However, Klinowski and 
Paulsen, (2013) have proposed a different awareness pathway, suggesting that 
unawareness is intrinsic to the neurological condition, originating from the 
neuropathological changes in brain structure rather than the impact of adjustment 
reactions.  
 
This lack of awareness can have significant impact on day to day functioning and 
emotional state of patients with chronic neurological conditions (Rosen, 2011).  Schrag 
et al’s (2001) regression analysis suggested that depression in Parkinson’s disease was 
more strongly influenced by the patients’ perceptions of illness than by their actual 
disability. Mediating factors, such as personality traits or social circumstances, may  
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increase disability or act as sources of resilience in patients with the same level of 
disease severity or impairment. The limited evidence base suggests that awareness of 
affective states, motor and cognitive abilities may be impaired in individuals with PD. 
Awareness is not an all-encompassing phenomenon as PD individuals can be 
differentially aware of deficits in various domains of functioning (Peto et al, 1995; 
Muslimovic et al, 2005).   
 
Previous systematic reviews have focused on either prevalence rates of depression 
and/or correlates and risk factors of depression in PD (e.g. age of onset and duration of 
illness) rather than psychological variables (e.g. awareness of disability). Current 
research findings suggest that awareness of illness has an impact on emotional 
responses such as depression. However, the interaction between risk and awareness 
factors of depression in PD has not been reviewed. 
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Aims and Research Questions 
This systematic review aims to highlight the most consistently reported factors 
(descriptive features and risk factors) and possible underlying psychological 
mechanisms (awareness) associated in the presence of depression in individuals with 
PD.  
1. Determine the extent that current research into PD, awareness, 
depression and risk factors include standardised measures of mood and severity of 
PD.  
 
2. What elevates the risk of depression in PD? Describe the most 
consistently reported risk factors of depression in PD. 
 
3. Examine the association between awareness and depression in PD. In 
particular, does greater awareness of PD symptoms affect the likelihood of 
depression? 
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Methods 
This systematic review adhered to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement guidelines (PRISMA; Moher et al., 2009; 
Liberati et al., 2009). A search of the Database of Abstracts of Reviews of Effects and 
the Cochrane Database of Systematic Reviews was completed. No existing or ongoing, 
literature reviews, systematic reviews or meta-analyses into this area were identified.  
 
A systematic search of electronic databases was conducted to identify all existing 
research articles, assessing descriptive factors and risk factors of depression and aspects 
of awareness among adults with Parkinson’s disease. The following databases and 
search platforms were used: Medline (via OVID Medline (R) 1946 to May week 1 
2015.) Embase (via OVID Embase, 1947 to present, updated daily on 5th May 2015) 
CINAHL, PsycArticles and PsycInfo (via EBSCOhost 1987 until 5th May 2015). In 
addition to the database searches, a hand search was completed on the journal 
‘Movement Disorders’, a key journal in the field of Parkinson’s disease (for the last 
three years, from May 2012 – April 2015). In order to identify any articles of relevance 
which may not have been identified by the electronic searches, hand searches were 
completed on the reference lists of the key articles found in the database searches.  
 
After considering previous systematic reviews of PD and depression (Sagna et al, 2014) 
and reviewing current literature, the following search terms were used: 
 (*Asterisk indicates truncation of words).  
1. Parkinson’s disease/ OR Parkinson disease/ OR Young Onset Parkinson’s 
disease OR Parkinson*  
2. Depressive Disorder/ OR Depressive Disorders OR Major Depressive Disorder/ 
OR Major Depression/ OR Depression/ OR Depress* OR Adjustment Disorder/ 
OR Adjustment Disorders/ 
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3. Awareness/ OR Unawareness OR Insight; Judgement OR Judgment/ OR 
Anosognosia.  
4. Risk Factor/ OR Risk Factors/ OR Risk factors for depression OR Predictor* 
OR Correlate* OR Association/ OR Associate* OR Descriptive* OR 
Descriptive feature* OR Descriptor*  
 
All search terms were combined with the Boolean operator ‘AND’ (1 AND 2 AND 3 
AND 4). 
 
Date of publication limitations were specified to include all articles published until 5th 
May 2015. Articles were screened for eligibility through scrutiny of titles and abstracts, 
with a detailed review being conducted on those retrieved for inclusion against the 
following criteria: 1. Peer-reviewed articles published in the English language; limited 
to human studies with adult participants (over 18 years); 2. Studies were limited to 
original published research (Cohort studies, observational studies, intervention studies, 
randomised control trials, experimental studies, cross-sectional and descriptive studies) 
3. Participants had a diagnosis of PD based on a standardised diagnostic measure. 4. 
Depressive symptoms were measured using a standardised instrument (e.g. Hospital 
Anxiety and Depressive Scale - HADS). 5. Risk factors or correlates of depression are 
reported. 6. Awareness of PD symptoms is reported or described.  
 
Papers were excluded if they were: 1. Unpublished research, review articles, books, 
book reviews, poster presentations/ conference abstracts, Editorials; 2. Studies with no 
data or qualitative data; 3. Presence of neurological disorders other than PD  (e.g. 
Traumatic Brain Injury; Dementia; Stroke or mixed neurological populations). 4. 
Participants with diagnosis of other mental health disorders. (Please see Appendix 1.2 
for data extraction form). 
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Endnote was used to store and manage all references identified by the search. This 
reference manager also enabled duplicates to be removed. If eligibility for inclusion 
remained unclear, a researcher independent of the project reviewed the article.  
 
Search Results 
Electronic and hand searches identified 249 citations, which, once duplicates were 
removed left 196 unique citations to be screened for inclusion. Their titles and abstracts 
were assessed for their relevance to the review, resulting in 27 potential citations being 
retained. The full texts of these papers were obtained. After applying inclusion criteria 
to these full text papers, 18 papers were excluded. Therefore 9 papers were included in 
this systematic review. As stipulated in PRISMA, a four-phase flow diagram was 
produced to document the flow of information through the different phases of the 
systematic review (identification, screening, eligibility and included studies). Figure 1 
illustrates the PRISMA Flowchart selection process. 
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Figure1. PRISMA Flow diagram  
196 citations left after duplicate records 
removed 
 
Title/abstract of 196 
citations screened 
169citations excluded 
 
Full-text of 27 articles 
assessed for eligibility 
 
18 Full-text articles excluded 
due to the following reasons: 
 
Included participants with other 
mental health conditions (n = 6) 
Included participants with other 
neurological conditions (n= 1) 
Did not include standardised 
measure of PD (n=1)  
Did not include measure of 
depression (n=4) 
Did not include risk 
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depression or awareness (n=6) 
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Methodological Quality Rating 
The Crowe Critical Appraisal Tool (CCAT; Crowe 2013) was used to quality rate 
studies. The CCAT consists of 22 items divided into eight categories reflecting the 
content of a typical research paper: Preliminaries, Introduction, Research Design, 
Sampling, Data Collection, Ethical Matters, Results and Discussion.  Each category is 
scored on a 6 point scale, with the lowest score for each category being 0 and the 
highest score 5. The overall CCAT score for a single paper that can be achieved is 
expressed out of 40 and then converted to an overall percentage. The ratings for each of 
the studies in relation to the quality criteria are shown in Appendix 1.3.  
 
In order to ensure reliability and increase confidence in quality rating, all identified 
papers were reviewed and co-rated by a fellow Trainee Clinical Psychologist, who was 
independent of the study. Quality rating process: each reviewer rated five papers, this 
was then followed by a discussion of individual ratings. Agreement (within two marks) 
of the total quality score was found in 4 of 5 (80%) co-rated papers, and agreement 
(within one mark) was found for the remaining article. Points of disagreement were 
resolved through discussions, with disagreed ratings amended to the consensus. The 
remaining four articles were then independently rated, following a second discussion all 
four papers received the same mark from both reviewers. Overall, quality rating 
agreement was high.  
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Results and Discussion 
Data Synthesis  
It is necessary to consider the overall findings of highlighted studies in respect of their 
collective methodological strengths and weaknesses. As the studies identified for 
inclusion in this systematic review varied in terms of their methodology, standardised 
measures and statistical analysis, it was decided that a narrative synthesis would be 
used. This is a textual approach to collating and appraising findings from multiple 
studies and allows for the analysis of relationships between them (Popay et al., 2006). 
For clarity of presentation, the evidence for each aim of the systematic review will be 
examined separately.  
 
In order to gather the relevant data from each study for inclusion in the systematic 
review, a data extraction form was devised (Appendix 1.2). In regards to risk factors 
associated with depression in PD, a table was created based on key clinical and 
demographic features of depression, as stipulated in the criteria for Major Depressive 
Episode: DSM-V (American Psychiatric Association, 2013) and from the knowledge 
base of depression in PD (Dissanayaka et al, 2011, Sagna et al, 2014 & Schrag et al, 
2001). Though the use of a vote counting procedure, each feature was allocated to a risk 
factor category: Behavioural, Clinical, Cognitive, Motor and Physiological.  
 
General Characteristics of Studies 
Based on the CCAT, the overall methodological quality of included studies had a mean 
total score of 29.1 (73.1%), with scores ranging from 27 - 31 (range of 68 - 78%). Four 
of the nine studies reported risk factors and correlates of depressive symptoms in 
individuals with PD. Table 1 summarises participant’s characteristics of these four 
studies. The remaining five studies used a level of awareness measure and specifically 
explored the relationship between depression and level of awareness. Participant 
characteristics of these five studies are summarised in Table 2. 
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Table 1.  Summary of participant’s characteristic and measures - studies on risk factors and depression in PD. 
 
Study Overall 
Quality 
Rating 
Total  % 
 
Purpose  Sample Size and Characteristics Standardised 
measure of PD 
Standardised 
measure of 
Depression 
Other Measures Consideration of 
Pharmacological 
/Psychological 
Interventions  
Farabaugh 
et al (2009) 
29 73 
 
Examined the 
frequency of risk 
factors speciﬁc to 
depressive symptoms 
in PD. 
158 patients with PD (108 men and 
50 women; mean age 66.82 years, 
range 39 – 74years. 
 
Mean disease duration 9.1 years, 
range 7-20 years. 
 
Mean age of onset 57.7 years  
H&Y HANDS n/a 70 Participants 
currently prescribed  
Anti-depressant 
medication. 
Saez-
Francas et 
al (2013) 
30 75 
 
Evaluated the 
relationship between 
apathy and central 
fatigue in PD patients. 
Total sample size of 90 PD patients. 
60 male, 30 female. 
Mean age 61.44 years  
 
Fatigued group Gender 22 male to 15 
female. 
Mean age 62.2 years  
Mean age of onset 58.3 years  
H&Y 
UPDRS 
HAM-D Cognitive 
MMSE 
 
Mood 
LARS 
STAI 
 
Other  
All PD participants 
were prescribed 
Anti-parkinsonian 
medication and were 
on the ‘on state’ of 
medication when 
tests were 
administered. 
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Abbreviations: BDI = Beck Depression Inventory; HAM-D = Hamilton Depression scale; HANDS = Harvard Department of Psychiatry/National Depression Screening Day Scale; 
H&Y = Hoehn & Yahr Staging Score; LARS = The Lille Apathy Rating Scale; MMSE = Mini Mental State Examination; PDQ-39 = Parkinson’s disease Questionnaire; PFS = The 
Parkinson Fatigue Scale; SE = Schwab-England Scale; SPES/SCOPA = Short Parkinson's Evaluation Scale/Scales for Outcomes in Parkinson’s disease (SCOPA-AUT: autonomic 
function; SCOPA-COG; cognition; SCOPA-MOTOR: motor; SCOPA-SLEEP; sleep); STAI = State-Trait Anxiety Inventory State; UPDRS = Uniﬁed Parkinson’s disease Rating Scale. 
 
Non-fatigued group Gender 38 males 
to 15 females. 
Mean age 62.8 years (9.6). 
Mean age of onset 58.5 years (10.2) 
PFS 
 
 
 
 
 
 
 
 
 
 
Schrag et 
al (2001) 
29 73 
 
Investigated factors 
that may contribute to 
depression in PD. 
97 PD individuals. 
Gender; 50 men and 47 women 
Mean age in years was 73 Mean 
disease duration 5.8 years 
Mean age of onset age 67.6 years.  
H&Y 
UPDRS 
SE 
 
BDI Cognitive 
MMSE 
 
Quality of Life 
PDQ-39 
 
All PD participants 
were prescribed 
Anti-parkinsonian 
medication. 
Verbaan et 
al (2007) 
28 70 
 
1. Evaluated the 
occurrence of 
Autonomic Symptoms 
(AS) in PD, compared 
to the occurrence of 
AS in control subjects.  
 
2. Explored the 
association between 
demographic, disease-
related and clinical 
variables in this PD 
cohort. 
420 patients with idiopathic PD (64% 
men and 36% female; mean age 61.1 
yr; range 39 – 74yrs. 
 
Mean disease duration 10.5 years  
Mean age of onset 50.6 years  
 
Severity of PD 
217 – mild PD 
110 – moderate PD 
82 severe PD (missing data 11 
patients).  
 
150 control participants of with 55% 
were male and 45% female. Mean 
age 60.9 years  
Diagnosis based on 
the United 
Kingdom PD 
Society Brain 
Bank criteria for 
idiopathic PD. 
SCOPA-AUT 
H&Y 
BDI 
 
Motor/movement 
SPES/SCOPA-motor 
 
Cognitive 
SCOPA-COG 
 
Mood 
Modified-PPRS 
 
Other 
 
SCOPA-SLEEP  
 
397 PD participants 
were prescribed 
Anti-parkinsonian 
medication and were 
on the ‘on state’ of 
medication when 
tests were 
administered. 
 
23 PD participants 
were not prescribed 
Anti-parkinsonian 
medication. 
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Table 2.  Summary of participant’s characteristic and measures - studies on depression and awareness in PD. 
Study Overall Quality 
Rating 
Total  % 
 
Sample Size and 
Characteristics 
Standardised 
measure of 
PD 
Standardised 
measure of 
Depression 
Measures of Awareness 
 
 
Other Measures 
 
 
Consideration of 
Pharmacological 
/Psychological 
Interventions 
Amanzio 
et al 
(2010) 
29 73 
 
25 PD patients and observers 
(12 men and 13 women; 
mean age 59.12 yrs, range 
39 – 74yrs. 
 
Mean disease duration   
137.60 months, range 84-
240. 
 
H&Y 
UPDRS (Parts 
III & IV) 
HAM-D Movement Disorders 
GAM 
 
Dyskinesia Rating Scale 
 
Hypo-bradykinesia rating 
scale. 
 
Awareness of 
disabilities in activities 
of daily living 
NUDS 
Motor/movement 
UPDRS Parts III & IV 
 
Cognitive 
MMSE 
WMS subtests IV & 
VII 
Claridge modified test 
WCST modified  
Phonemic Fluency Test 
 
Mood 
 
HAM-A 
BPRS 
 
 
All PD participants 
were prescribed 
Anti-parkinsonian 
medication.  Tests 
were administered 
on both the ‘on 
state’ and ‘off state’ 
of PD medication. 
 
PD participants 
were excluded if 
diagnosed with 
depression or if 
prescribed; Anti-
depressant, 
Neuroleptics or 
Anxiolytic 
medication. 
 
Brown et 
al  
(1989) 
29 73 
 
66 patients with PD (43 men 
and 23 women; mean age 
58.6 yr, range 39 – 74yrs. 
 
Mean disease duration 10.7 
years  
 
Mean age of onset 48.9 
H&Y 
King’s 
College 
London 
Parkinson’s 
disease Rating 
Scale. 
BDI ADL 
 
Cognitive 
MMSE 
 
 
 
 
 
 
All PD participants 
were prescribed 
Anti-parkinsonian 
medication. 
 
37 Participants 
were involved in an 
intervention study 
DClinPsy 2015 University of Glasgow 
Page | 23 
 
years  
 
 
 
examining 
psychosocial 
function in PD. 
 
29 participants were 
involved in a study 
examining sexual 
function in PD.  
 
Lehrner 
et al 
(2015) 
31 78 
 
PD  cognitively healthy 
group – 28 (17 men and 11 
women)  
 
Mean age 67 yrs; range 52 – 
81 yrs). 
 
 
Cognitively healthy Control 
Group – 211 (77 men and 
134 women; mean age 66 yr; 
range 50 – 93yrs. 
Criteria for control:  MMSE 
score ≥27 & MOCA score 
≥26. No active neurological 
or psychiatric disease, no 
psychotropic medication and 
no medical disorder or 
treatment that negatively 
affects cognitive 
functioning. 
 
 
Diagnosis 
based on the 
criteria of the 
UK 
Parkinson’s 
disease 
Society Brain 
Bank. 
 
H & Y 
BDI-II VSRT (objective) 
FAI (subjective)  
 
Motor/movement 
B-ADL 
 
Cognitive 
NTBV 
MMSE 
WST 
 
Exclusion criteria: 
All individuals with 
a diagnosis of 
depression.  
Individuals 
prescribed 
psychotropic 
medication. 
 
 
 
 
 
 
 
Sitek et 
al  
30 75 
 
45 PD patient – observer 
pairs (26 men and 19 
H & Y  
UPDRS 
BDI 
MADRS 
SRSMF Motor/movement 
UPDRS Parts III & IV 
All PD participants 
were prescribed 
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Abbreviations: ADL = Activities of Daily Living; AVLT = Auditory Verbal Learning Test; B-ADL = Bayer Activities of Daily Living Scale; BDI = Beck Depression Inventory; 
BDI-II = Beck Depression Inventory-II; BPRS = Brief Psychiatric Rating Scale; FAI = The Forgetfulness Assessment Inventory; GAM = Global Awareness of Movement disorders 
scale;; HAM-A = Hamilton Anxiety Scale; HAM-D = Hamilton Depression scale; H&Y = Hoehn & Yahr Staging Score; MADRS = Montgomery – Asberg Depression Rating 
Scale; MMSE = Mini Mental State Examination; NTBV = The Neuropsychological Test Battery Vienna; NUDS = The North University Disability Scale; SE = Schwab-England 
Scale; SPDDS = Self-Assessment Parkinson’s disease Disability Scale; SRSMF – Self-Rating Scale of Memory Functions; UHDRS = Unified Huntington’s Disease Rating Scale; 
UPDRS = Uniﬁed Parkinson’s disease Rating Scale; VSRT = The Verbal Selective Reminding Test; WCST = Wisconsin Card Sorting Test; WMS = Wechsler Memory Scale; WST 
= Wortschatztest. 
 
(2011a) women; observers included 
33 spouses, 9 children and 3 
patient friends) mean age 
64.98 yr,) range 40 – 84yrs. 
 
Median disease duration in 
years 8 (range 2 – 24) 
 
Age of onset Mean 56.58 
years, range 33 – 75 
 
SE  
Cognitive 
MMSE 
AVLT 
Stroop test 
 
Anti-parkinsonian 
medication. 
 
 
 
 
 
 
 
Sitek et 
al 
(2011b) 
27 68 
 
21 patients with idiopathic 
PD (10 men, 11 women) 
mean age: 63.29 years, range 
40-78 years. 
 
Mean disease duration 12.19 
years, range 5 – 24 years. 
 
Each PD individual was part 
of an observer partnership. 
(14 spouses and 7 children). 
 
 
H & Y scale 
UPDRS parts 
II & IV 
SE 
 
BDI Questionnaires 
comprising of dyskinesia 
items from; UHDRS, 
UPDRS and SPDDS. 
Cognitive 
MMSE 
Stroop Task 
 
 
 
 
All PD participants 
were prescribed 
Anti-parkinsonian 
medication and 
were on the ‘on 
state’ of medication 
when tests were 
administered. 
PD participants 
were excluded if 
prescribed 
Anticholinergic 
medication. 
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Participants 
The sample sizes of the experimental groups of all nine studies ranged from 21 to 420 
participants. The mean age of the participants ranged from 58.6 years to 73.0 years. 
Mean age of onset ranged from 48.9 years to 67.6 years (documented in six studies) and 
mean duration of disease 5.8 years to 12.9 years (documented in seven studies). 
Information on the gender of participants was provided by all studies, with an overall 
sample of 595 Males to 355 Females. 
 
 
Measurement of Depression 
Eight studies measured depression by self-report measures (Amanzio et al, 2010; Brown 
et al, 1989; Farabaugh et al, 2009; Lehrner et al, 2015; Saez-Francas et al, 2013; Schrag 
et al, 2001; Sitek et al, 2011b & Verbaan et al, 2007). The most common self-report 
measure used was the Beck Depression Inventory I/II (BDI - six studies), followed by 
the Hamilton Depression Scale (HAM-D– two studies) and the Harvard Department of 
Psychiatry/National Depression Screening Day Scale (HANDS – one study). The 
remaining study by Sitek et al (2011a) utilized both clinician and self-report measures 
of depression using the BDI and the Montgomery – Asberg Depression Rating Scale 
(MADRS). All standardised depression measures utilized by the studies have been 
found to be reliable and valid scales of measurement in PD, especially the BDI (Sagna 
et al, 2014).  
 
The results of the measurements of depression must be viewed in light of several 
limitations. The overwhelming reliance of self-report measures in all studies may give 
rise to subjective bias from the participants (Farabaugh et al, 2009). Due to differences 
between self-rating measures and clinician rated scales, in terms of mode of 
administration and symptoms assessed, Uher et al (2012) propose that a complete 
assessment of depression should include both clinician-rated scales and self-reported 
measures. Although, Sitek et al (2011a) utilised two methods of depression 
measurements (self-rating and clinician rating) they did not document who administered 
the MADRS or whether the objective rater was qualified to administer the measure.  
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In terms of pharmacological and/or psychological treatment, eight of the nine studies 
reported that PD individuals who were currently prescribed anti-Parkinsonian 
medication were involved in the studies. Of these eight studies, three (Saez-Francas et 
al, 2013; Sitek et al, 2011b; Verbaan et al, 2007) only administered tests when 
individuals  were on the ‘on state’ of the anti-Parkinsonian medication and one study 
(Amanzio et al, 2010) compared PD individuals in both ‘on and off state’. In terms of 
other pharmacological and psychological interventions, only two studies documented 
the exclusion criteria of anti-depressants/ psychotropic medication (Amanzio et al, 2010 
& Lehrner et al, 2013). Brown et al (1989) was the only study to document whether PD 
individuals were receiving psychological interventions. Overall, conclusions of all nine 
studies must take into consideration the potentially confounding factors involved in 
either receiving/ not receiving additional interventions on the study outcomes. 
 
 
Measurement of PD Severity 
In terms of standardised measures of PD diagnosis/disease severity, all nine studies used 
the clinician rated Hoehn & Yahr Staging Scale of PD (H&Y). Seven studies provided 
supplementary standardised measures of PD severity; five studies used the UPDRS 
standardised scale of motor symptom severity. The Schwab – England Scale (SE) was 
used in three studies; Diagnosis based on criteria of the UK Parkinson’s disease Society 
Brain Bank was used in two studies; The SCOPA-AUT was used in one study; The 
King’s College London Parkinson’s disease Rating Scale was used in one study. 
 
 
What elevates the risk of depression in PD? Describe the most consistently reported 
risk factors of depression in PD. 
 
Risk factors associated with depression in individuals with PD were examined in four of 
the nine included studies (Table 1). The majority of these studies used cross-sectional 
designs (Saez-Francas et al, 2013; Farabaugh et al, 2009; Verbaan et al (2007). The 
remaining study was a population based cohort study (Schrag et al, 2001). The sample 
sizes of these studies ranged from 90 – 420 and the mean ages of the samples ranged 
from 61.1 to 73.0 years. Through the vote counting procedure, 17 risk factors associated  
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with PD and depression were identified in these papers. These risk factors were divided 
into different sub-types: clinical (7), motor (5), cognitive (3) and physiological (2). 
(Table 3 - Summary of key descriptive features and risk factors of depression in PD). 
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 Table 3. Summary of key descriptive features and risk factors of depression in PD  
Risk Factor Subtype 
 
Clinical-
Demographic 
Correlate 
Association with Depression Study 
Clinical Factors    
 Gender No significant effect  
 
Schrag et al (2001) 
Age No significant difference with current age above or below 60 years. Schrag et al (2001) 
Age of Onset No significant difference between depression and age of onset 
(before or after 55 years). 
Schrag et al (2001) 
Stage of Disease/ 
Severity of PD 
Significant effect (p<0.05) 
Strong and significant positive effect was found between Hoehn & 
Yahr score and ratings of hopelessness (p<0.0062). 
Farabaugh et al 
(2009) 
 
Signiﬁcant correlation (p<0.001) Schrag et al (2001) 
Duration of illness No significant association  Farabaugh et al 
(2009)   &  
Schrag et al (2001) 
Premorbid 
psychiatric Condition 
– depression 
Significant association found between history of depression prior 
to PD diagnosis and severity of depressive symptoms (HANDS, 
p<0.001).  
Farabaugh et al 
(2009)  
DClinPsy 2015 University of Glasgow 
Page | 29 
 
Suicidal Ideation Strong association was shown between history of depression and 
suicidal ideation (p<0.0001) 
Farabaugh et al 
(2009) 
Physiological Factors    
 Autonomic 
Symptoms  
Significant correlation ( p<0.01) 
 
Verbaan et al 
(2007) 
Fatigue Significant difference in severity of depressive symptoms between 
PD patients with fatigue and PD without fatigue (p<0.001). 
Saez-Francas et al 
(2013) 
Cognitive Factors    
 
 
 
Awareness Significant difference (p<0.001). Schrag et al (2001) 
Cognitive 
Impairment 
Significant association between cognitive deterioration and severity 
of depression. (p<0.0001). 
Schrag et al (2001) 
Strong association was shown between history of depression and 
poor concentration (p<0.001). 
Farabaugh et al 
(2009) 
Hallucinations Depression scores were significantly higher in individuals who 
self-reported hallucinations (p<0.05) 
Motor Factors    
 Balance/Falls Depression scores were significantly higher in individuals who 
reported falls (p<0.01) 
Schrag et al (2001) 
Dyskinesia No significant association  
Tremor Correlation found between level of depression and higher tremor 
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scores (p<0.05) 
Bradykinesia /  
Stiffness 
Significant correlation between depression and higher akinesia 
scores (p<0.01)  
Depression scores were significantly higher in individuals who 
self-reported stiffness (p<0.05) 
Dexterity or Speech Depression scores were significantly higher in individuals who 
self-reported impairment of dexterity or speech (p<0.05) 
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Through the application of vote-counting, seven clinical risk factors were identified in 
two studies (Farabaugh et al, 2009 & Schrag et al, 2001). Both studies found a 
significant positive association between severity of depression and stage of disease, 
with higher depression scores associated with advancing disease severity.  Farabaugh et 
al, (2009) found a significant correlation between H&Y score and ratings of 
hopelessness, as PD individuals with higher H&Y scores exhibited higher ratings of 
hopelessness and were more likely to be diagnosed with depression.  However, no 
association was found between duration of illness and level of depression (Farabaugh et 
al, 2009; Schrag et al, 2001). Schrag et al, 2001 examined the clinical factors of gender, 
current age and age of onset. No significant associations were found between depression 
scores and gender or between level of depression and current age above or below 60 
years. No significant difference was found between depression and age of onset before 
or after 55 years.  
 
Individuals with premorbid depression prior to PD diagnosis were signiﬁcantly more 
depressed than those who had no previous psychiatric history (Farabaugh et al, 2009). 
Following on from this finding, Farabaugh et al (2009) found a strong association 
between history of depression and suicidal ideation, with individuals with premorbid 
depression reporting a significantly higher frequency of suicidal thoughts.  
 
In regards to the motor category, one study identified five risk factors (Schrag et al, 
2001). Significant correlations were found between PD patients with higher depression 
scores and who self- reported; the presence of falls, tremor, bradykinesia, stiffness or 
impairment of dexterity and/or speech. However, no significant association was found 
between level of depression and self-reported dyskinesia.  
 
Cognitive risk factors were examined in two studies (Farabaugh et al, 2009 & Schrag et 
al, 2001). Schrag et al (2001) found a significant association between cognitive 
impairment and depression. With PD patients who scored  >25 on the Mini-Mental  
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MMSE being more likely to have a diagnosis of depression. Farabaugh et al (2009) 
found a significant correlation between level of depression and poor concentration, and 
a significant relationship between numbers of self-reported hallucinations with higher 
depressive scores.  
 
The cognitive risk factor of awareness was examined by Schrag et al (2001). This study 
compared PD participants self-rating of disability to that of clinician’s objective ratings. 
Results suggested the level of depression in PD was strongly inﬂuenced by the patients’ 
perceptions of disability rather than by their actual disability. PD patients with BDI 
scores of >18, rated their disability greater than the clinician. In comparison, PD 
patients with BDI scores <18 rated their level of disability similarly to clinicians. Over 
90% of patients with depression scores  >18, were rated on stages of 3, 4 or 5 of the 
H&Y Scale. This suggests that individuals with higher H&Y score perceived 
themselves to be more disabled and were at an increased likelihood of reporting 
symptoms of depression. However, a small proportion of patients with moderate to 
severe depression were found to be at the early stages of illness, lower staging on H&Y. 
These individuals may represent the subtype of depressed PD patients proposed by 
Tandberg et al (1997), who exhibit depressive symptoms as a reaction to diagnosis. 
 
Physiological risk factors were examined in two studies (Verbaan, et al, 2007 & Saez-
Francas et al, 2013). Verbaan et al (2007) found a significant correlation between 
autonomic dysfunction (symptoms that relate to cardiovascular, gastrointestinal, 
urinary, thermoregulatory, pupillomotor, and sexual functioning) and depressive 
symptoms. Suggesting that increasing severity of autonomic symptoms in PD 
individuals was associated with increasing severity of depressive symptoms. Saez-
Francas et al (2013) found a significant association between depression and fatigue, as 
PD patients with fatigue showed a significantly higher score of depression than non-
fatigued PD participants.  
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Methodological Limitations of Reviewed Literature 
Methodological limitations of these studies, included a lack of psychiatric diagnosis of 
depression, as depression was measured using patient self-rating scores, such as the 
BDI. Therefore all analysis have been completed on a prevalence rate that relates to the 
proportion of patients scoring highly on that scale, rather than the presence of a 
depressive illness. This reliance on self-report measures may have an inherent 
subjective bias (Schrag et al, 2001).   
 
 
Summary of Results 
The majority of studies were cross-sectional studies that used standardised measures of 
depression and PD severity. Four research studies were identified that reported 17 risk 
factors of depression in PD. It must be noted that methodological issues were apparent 
in these studies. The finding of a discrepancy between subjective and objective clinician 
rating of disability by Schrag et al (2001), highlights the important role that awareness 
of abilities may play in PD and depression. Although, Schrag et al (2001) did not 
include a standardised measure of awareness, the findings from this article provide 
background to the association between awareness and depression. 
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The Association Between Awareness and Depression in PD.  
The association between awareness and depressive symptoms in individuals with PD 
was examined in five of the nine studies.  All five studies were observational in design; 
four cohort studies (Amanzio et al, 2010; Brown et al, 1989; Sitek et al, 2011a, & Sitek 
et al, 2011b) and one case-control study (Lehrner et al, 2015). Three of the studies 
focused on awareness of motor abilities and the remaining two studies focused on PD 
patient’s awareness of their memory functioning (Lehrner et al, 2015; Sitek et al, 
2011b). The sample sizes of these studies ranged from 21 – 60 and the mean age of 
samples ranged from 58.6 to 67.0 years.  
 
 
Assessment of Awareness 
All five studies applied a discrepancy method, whereby discrepancy ratings between 
self-reported levels of ability were compared against an objective rating.  However, 
three methods of awareness measurement were utilized within the five studies.  Two 
studies used PD patient - observer discrepancy ratings to produce a measure of 
awareness and compared these discrepancies against objective memory performance 
(actual performance) (Sitek et al, 2011a & Sitek et al, 2011b). Amanzio et al, (2010) 
and Brown et al, (1989) utilized two sources of objective discrepancy ratings, from 
observer and qualified clinicians, which were then compared to subjective ratings. The 
final study, (Lehrner et al, 2015) measured discrepancy ratings between PD patient’s 
subjective memory appraisals (estimation of performance) and objective memory 
performance (actual performance). These results were then compared to the discrepancy 
ratings of a control group of healthy volunteers. Table 4 outlines the study rationale, 
awareness measure and key findings of the five included studies. 
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Abbreviations: BDI = Beck Depression Inventory; HAM-D = Hamilton Depression scale; MADRS = Montgomery – Asberg Depression Rating Scale;  
* ADS = average difference score of the Self-Rating Scale of Memory Functions (SRSMF) 18 items between patient and observer recordings.    
**OS = overestimation scores (patient rated their memory abilities as more severely impaired than did their observer).  
 
 
Table 4. Association between awareness of abilities and depression in PD 
Study Purpose Awareness Method  Association  
Amanzio  et al 
(2010) 
To analyse the presence of awareness of movement 
(dyskinesia and hypokinesia) and motor fluctuations with 
mood.  
 
 
Discrepancy ratings between patients self-report of 
awareness of movement disorders and level of 
disability to observer evaluations. 
 
Significant association (p<0.001).  
Brown et al  
(1989) 
Assessed the accuracy of self-reported disability in 
activities of daily living and explored the possible influence 
of depression on self-report. 
 
Discrepancy ratings between PD individuals self-
reported level of ability and observer (relative) 
judgements on ADL measure. And discrepancy 
scores between PD self-reported and clinician-rated 
ability on motor task and symptom severity.  
BDI was unrelated to symptom severity or self-
reported disability. 
 
Lehrner et al 
(2015) 
Explored correlates of awareness and compared frequencies 
of subjective over and under-estimations. Comparison 
between PD and control group of healthy volunteers. 
 
Awareness of memory ability was measured as the 
difference between subjective memory appraisals 
and objective memory performance. 
 
No correlation was found between PD patients level of 
awareness and BDI scores.  
Sitek et al  
(2011a) 
 
 
This study examined self-awareness of dyskinesia and 
motor symptoms in PD.  
 
Discrepancy ratings were used by subtracting 
observer ratings from patient self-report on motor 
awareness questionnaire. 
No significant associations were found between 
awareness of motor ability and depression. 
Sitek et al 
(2011b) 
Assessed self-awareness of memory in PD by comparing 
patients’ and caregivers’ questionnaire ratings of the 
patients’ memory and by correlating subjective ratings with 
verbal learning results. Factors that could influence the self-
awareness of symptoms, such as mood, general cognitive 
status and disease severity were also assessed. 
 
Discrepancy ratings calculated by subtracting 
observer ratings from patients self-report on the 
adapted SRSMF (This study took place in Poland, 
the SRSMF was translated into Polish and 
demonstrated satisfactory consistency, Cronbach’s 
alpha of 0.92 and validity. The SRSMF  was adapted 
for use as an observer measure - satisfactory 
reliability (Cronbach’s alpha=0.89) 
 
Significant correlation were found between MADRS 
and ADS* (p<0.05), 
MADRS and OS** (p<0.001) and BDI and OS 
(p<0.01) 
 
 
DClinPsy 2015 University of Glasgow 
Page | 36 
 
 
Association between Motor Awareness and Depression 
Awareness of motor symptoms was examined in three of the included studies (Amanzio 
et al, 2010; Brown et al 1989, & Sitek et al, 2011a).  
 
Amanzio et al (2010) examined the ‘on-off states’ of motor fluctuations on awareness. 
The majority of PD individuals are prescribed dopaminergic medication, such as 
Levodopa, which alleviates the motor symptoms of PD. However, as the disease 
progresses research has been shown that this medication becomes less effective. As a 
result, individuals with PD are said to be in an ‘on state’ when the medication is 
effective. However, due to the medication ‘wearing off’ period, the person is then said 
to reach an ‘off state’, where they may exhibit an increase in motor symptoms, such as 
stiffness and rigidity (Lees, 1989).  
 
Amanzio et al (2010) found a significant association between severity of motor 
impairment, level of awareness and severity of depression. PD patients who scored 
higher on levels of depressive symptoms in the ‘off state’, reported higher awareness of 
motor impairment. It was also found that individuals with higher levels of depressive 
symptoms scored higher in areas of apathetic behaviour, such as lack of interest and 
reduced emotional responsiveness. Neuropsychological test results indicated a 
difference between on and off state for cognitive performance. Results showed that 
when in the ‘on state’ PD patients performed better on tests of executive functioning 
and memory, suggesting a possible link between severity of motor impairment and 
cognitive functioning, however no comparison was made in relation to level of 
awareness.  
 
Brown et al.’s (1989) study of self-rated disability of motor abilities, found that PD 
individuals provided accurate judgements of disability similar to those of observer 
ratings.  Overall, PD patient's BDI scores were unrelated to self-ratings of symptom 
severity, suggesting that there was no independent contributory factor of level of  
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depression with accuracy of motor awareness. Sitek et al (2011a) found no significant 
associations between awareness of motor ability and level of depression in PD. Results 
of this study suggested that patient’s perception of motor disability were consistent with 
observer ratings.  
 
 
Association between Awareness of Memory Functioning and Depression 
Awareness of memory functioning was examined in two studies (Sitek et al, 2011b& 
Lehrner et al, 2015).  
 
Sitek et al (2011b) cohort study found that self-awareness of memory functioning was 
negatively affected by depressive symptoms, as PD patients who rated higher levels of 
memory dysfunction recorded higher depression scores. Results also suggested that PD 
patient’s total subjective memory ratings and observer objective memory ratings did not 
differ significantly, suggesting that self-awareness of memory function is relatively 
preserved in PD. However, when individual domains were examined, better agreement 
was found in items of verbal recall and word finding difficulties. Whereas working 
memory ratings differed significantly, with PD participants rating these higher than 
observer. This may be due to these memory features being more implicit to the person.  
 
 
In contrast, Lehrner et al (2015) reported no association between PD patient’s 
awareness of memory ability and severity of depression. Findings also suggested 
relatively accurate self-appraisals in the PD group. This suggests that individuals who 
were less accurate at predicting memory functioning (either under or over estimating 
ability) were just as likely to report depressive symptoms as PD individuals with 
awareness. A particular strength of this study was the use of a healthy control group, 
however, no demographic or statistical data of the control group were presented. 
Lehrner et al (2015), also noted that inaccurate self-assessment can be observed in 
control participants, however no data was supplied on the actual frequency for this 
population.  
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Methodological Limitations of Reviewed Literature 
There are a number of methodological limitations which must be taken into 
consideration when examining the results of these five studies. All five studies used 
various methods and designs, which led to difficulty in providing direct comparisons 
between studies. Of the five studies, Lehrner et al (2015) was the only study to include a 
control group. However, the authors stated this was a convenience sample of control 
participants recruited through an advertisement, which they argue may have led to 
selection bias. 
 
 
Only Amanzio (2010) differentiated between patients with ‘on - off’ state motor 
fluctuations, which has been argued to be a significant contributor to depression in PD. 
However, this sample comprised of individuals with a higher degree of PD severity, 
therefore it may be difficult to generalise these results to PD patients at different stages 
of disease severity. None of the remaining four studies differentiated between the ‘on – 
off state’. In fact, Sitek et al’s (2011a) PD sample were only examined in the ‘on state’, 
suggesting that pharmalogical medication may have been alleviating the motor 
symptoms of PD, as no comparisons were made between awareness of disability and 
level of depression in the ‘off state’. 
 
 
Other limitations include no documentation of flow of participants or reasons why 
people did not participate in the research in any of the five studies. Therefore, it could 
be argued that non-participants may exhibit other symptoms than those displayed by the 
experimental groups. As no sample size calculations were documented it is unsure if 
statistical power was achieved for any of the five studies. 
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Summary of Results 
In summary, results from the five papers exploring the relationship between awareness 
and depression in PD were mixed. All studies administered a discrepancy rating scale to 
compute level of awareness of either memory or motor abilities. Two studies outlined a 
significant association between level of awareness and severity of depression (Amanzio 
et al 2010 & Sitek et al 2011b), whereas the remaining three studies reported no 
relationship between these two conditions. 
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Conclusions 
Our aim was to review current literature on aspects of awareness, depression and risk 
factors in PD. From the search strategy nine empirical studies were identified that met 
inclusion criteria for this systematic review. Although, this is a relatively small number 
of articles, to date the empirical research in this area has received little attention and as 
such, the available evidence is in its infancy. Nonetheless, supplementation of results 
with hand searching and searching reference lists of included papers provides 
confidence that all relevant research was included in this systematic review and that 
conclusions arising from this review can be based on the synthesis of all available 
evidence. Overall, all nine papers included standardised measures of PD severity/ 
diagnosis and depression. 
 
What elevates the risk of depression in PD? Describe the most consistently 
reported risk factors of depression in PD. 
Within the nine articles, four papers examined risk factors and descriptive features of 
depression in PD. Several risk factors were highlighted in the articles and these were 
divided into sub-domains of clinical, motor, physiological, cognitive and behavioural 
factors. Data extracted across all four studies suggested that the most commonly 
associated risk factors of depression in PD patients were related to PD symptoms rather 
than demographic characteristics (with the exception of dyskinesia, Schrag et al, 2001). 
Demographic characteristics such as age, gender and age of onset were not associated 
with depression in PD. Factors which elevated the risk of depression included: severity 
of disease, premorbid depression, motor and cognitive symptoms.  
 
Due to many depressive and PD symptoms overlapping, the use of standardised 
measures of depression may present difficulties to PD individuals, as questions could 
relate to either condition. Difficulties in differentiating between PD symptomology and 
depressive symptoms, may result in PD patients receiving inappropriate treatment and 
under-diagnosis of depression (Pachana, 2013). Modifiable factors that could be 
targeted to reduce adverse outcome such as distress and suffering, could include the  
DClinPsy 2015 University of Glasgow 
Page | 41 
 
 
development of specific tools sensitive to the unique characteristics demonstrated by 
this population. Through the application of standardised self-report measures, key 
depressive symptoms may be unrecognised due to their association with PD symptoms. 
It is hoped that findings from this review highlight the complex interaction between 
these two conditions and informs clinicians when assisting in the prevention and 
intervention of depression in PD patients. To summarise, previous literature (Sagna et al 
2014) has stated the equivocal nature of risk factors in PD and findings from this current 
systematic review further highlight this. 
 
Examine the association between awareness and depressive symptoms in PD. Does 
greater awareness of PD symptoms affect the likelihood of depression? 
Five studies explored the relationship between awareness and depressive symptoms in 
PD. Overall findings were mixed, with only two articles reporting an association 
between level of awareness of motor/memory impairments and severity of depression. 
Findings from Sitek et al (2011b) and Amanzio et al (2010) suggested that PD patients 
who were more aware of PD symptoms (memory and motor) were more likely to be 
depressed. With higher scores on awareness associated with higher depressive scores. 
Results from this systematic review suggest that awareness of illness may have an 
impact on depression. This is consistent with previous research, which stated that 
perception of illness rather than actual disability was a mediating factor of depression 
(Schrag et al, 2001).  
 
The mixed findings reported in this review may be due to a combination of study factors 
such as; different awareness measures, study design, sample size and characteristics of 
participants. For example, Amanzio et al (2010) was the only study to examine 
pharmalogical/medication factors. Results from this study suggested that when PD 
patients were experiencing motor fluctuations (‘off- state’) they were more aware of PD 
symptoms and self-reported higher depressive symptoms. However, when motor 
fluctuations were controlled through medication (‘on-state’) PD patients noted a 
reduction in depressive symptoms. The underlying mechanisms of unawareness 
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(intrinsic/reactive) still remains unclear and further research is needed into the possible 
relationship between awareness of PD symptoms and depression.  
 
Strengths and Limitations of the current review 
This is the first systematic review to be completed on PD, depression, awareness and 
risk factors. The results were limited to studies written in English. Parekh-Bhurke et al., 
(2011) suggested that an inherent publication bias is common when conducting a 
systematic review. However, the current review did include several quality rated papers 
which reported non-significant findings.  
 
The method of narrative synthesis used to analyse the articles within this review is a 
subjective method that can be open to several criticisms. In comparison to meta-
analysis, Popay et al (2006) stated that narrative synthesis could be regarded as the 
‘second best’ approach to synthesising data but, as noted in the Cochrane handbook: 
‘systematic reviews adopting a narrative approach to synthesis will be prone to bias, and 
may generate unsound conclusions,’ (2005; pg. 6). In order to reduce sources of 
subjective bias in this current review, both the inclusion/exclusion decisions and the 
quality ratings were subjected to independent review.  
 
Although the reliability and validity of Critical Appraisal Tools (CAT’s) have been 
questioned, such as arbitrary cut-off weightings of what constitutes good quality 
evidence from moderate and poor quality studies (Crowe & Sheppard, 2011). The 
CCAT utilized in the current review was devised from a systematic review of over 40 
CAT’s. A key strength of the CCAT was that scores were not converted into a 
scale/weighting, with each study evaluated on its own merit. This allowed for a 
narrative comparisons between scores rather than a numerical comparison, which may 
have masked methodological or design defects. Overall, applying a transparent and 
potentially replicable method of narrative synthesis to the current review allowed for the 
collation of evidence from several empirical studies, which highlighted a gap in the 
research knowledge base.  
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Clinical Implications & Future Research 
Findings from the four studies examining risk factors and descriptive features of 
depression in PD, suggest that the most commonly associated risk factors of depression 
in PD patients were related to PD symptoms. Although some of the papers included in 
this review offered evidence of an association between level of awareness and 
depression, this relationship was not reported across the five studies. Results from this 
review have documented the methodological limitations within the existing evidence 
base which may inform the development of new studies examining associations 
between level of awareness and depression. It is suggested that additional research with 
higher degree of methodological rigour is needed to allow for more consistent 
conclusions to be drawn.  
 
The majority of the included studies examining the relationship between awareness and 
depression either focused primarily on motor or memory abilities. As PD patients may 
experience impairments in both their motor and cognitive abilities it would be 
interesting to explore the differences of PD patient’s level of awareness between these 
two domains. Moreover, it would be beneficial to explore the potential relationship 
between specific motor and cognitive domains. Results of this review highlighted that 
only the cognitive domain of memory was assessed. It is suggested that future studies 
examine other cognitive domains such as; attention, concentration, visuospatial abilities, 
problem solving and executive functioning. This may allow clinicians to further 
understand the impact of these cognitive domains on severity of depression in 
individuals with PD.  
 
In terms of methodological limitations, it is proposed that future studies should be 
adequately powered and sample size calculations should be made available to aid cross  
study comparisons. In terms of impact of PD on depressive symptoms and level of 
awareness, the employment of a control group of healthy volunteers would allow for 
more robust comparisons to be examined. 
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Overall Conclusion  
In summary, this systematic review extracted data from the available literature base of 
PD, depression, awareness and risk factors. A relatively small evidence base exists of 
the association between level of awareness and severity of depressive symptoms, with 
mixed results from the included studies. The available research has several 
methodological limitations and it is recommended that further good quality empirical 
research is needed in this area. Insight into this relationship between awareness and 
depression may have clinical implications in the assessment, diagnosis and treatment of 
depression in individuals with PD. 
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Plain English Summary 
Background: Awareness of our abilities is important in everyday life as it supports the 
ability to recognise our limits. This ability is commonly weakened in neurological 
diseases, such as Parkinson’s disease (PD). Awareness is important in PD as it can 
impact on everyday functioning, ability to judge risks and may cause difficulties in 
relationships. Although several studies have examined level of unawareness of motor 
symptoms in people with PD, there has been limited research into PD people’s 
unawareness of cognitive abilities; attention and memory. 
  
Aims: The aim of this study was to explore unawareness of cognitive abilities in people 
with PD. This study also explored the differences between unawareness of cognitive 
abilities and motor abilities, and investigated how the person’s unawareness of 
cognitive abilities might affect their caregivers.  
    
Methods: This study comprised of two groups: an experimental group of people with 
PD and a control group of healthy volunteers (recruited from an advertisement in local 
GP surgeries). Participants included in the study had no history of learning disabilities; 
no current psychiatric disorder (e.g. depression); no substance misuse; nor previous 
neurological conditions (e.g. Traumatic Brain Injury; Stroke). Due to PD being a 
progressive illness, we decided not to include people at the more severe stages on the 
Hoehn and Yahr (1967) rating scale, as their motor and physical disabilities may be too 
severe for them to complete the tests.   
 
 Both groups were asked to predict their performance before completing the cognitive 
tests. After completing the tasks, all participants were asked to estimate their actual 
performance. This allowed us to calculate each participants level of unawareness by 
comparing their before and after ratings to their actual performance. The PD 
participants also completed an unawareness questionnaire and a motor test (finger 
tapping and heel lifts). 15 PD participants consented to having a family member 
complete a caregiver questionnaire. 
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Main Findings: We found that PD people overestimated their cognitive abilities 
compared to the healthy controls. PD people also showed a difference between their 
cognitive unawareness and motor unawareness. They tended to underestimate their 
motor abilities compared to their cognitive abilities. We also found a significant 
relationship between level of cognitive abilities and caregiver stress. This meant that PD 
people who were less aware of their cognitive abilities had carers who reported more 
stress. 
 
Conclusions: Results from this study suggest that people with PD show unawareness of 
their cognitive abilities compared to the healthy controls. It is hoped this project will 
further our understanding of unawareness of cognitive abilities in PD and what this 
means for people with PD, their carers and clinicians in a practical and functional sense.  
  
References: Hoehn, M.M., &Yahr, M.D. (1967) Parkinsonism: onset, progression and 
mortality. Neurology, 17 pp.427–442. 
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Abstract 
Background: ‘Anosognosia’, or unawareness of ones deficits, is an important influence 
on behavioural functioning as it underpins the ability to recognise our limits. 
Anosognosia is common in neurological diseases, such as Parkinson’s disease (PD). 
Although several studies have examined PD patient’s level of unawareness of motor 
symptoms there has been no research into PD patient’s unawareness of cognitive 
abilities. Aims: This study aimed to explore PD patient’s unawareness of their cognitive 
abilities in comparison to a healthy control group. We also explored differences in level 
of unawareness of cognitive abilities versus motor abilities. Finally, we explored the 
relationship between level of unawareness of cognitive abilities and caregiver burden. 
Methods: 21 PD participants and 21 control participants, with similar demographic 
characteristics, participated in this study. All participants predicted their performance 
based on a normal distribution curve, prior to completing the RBANS assessment. 
Following task completion, participants were then asked to estimate their actual 
performance. This resulted in a pre and post discrepancy score of the differences 
between self-rated and actual performances. The PD participants completed additional 
measures, including the Awareness Questionnaire and MDS-UPDRS-Part 3 (pre and 
post discrepancy). Fifteen PD participants consented to a significant other completing 
the Zarit Burden Interview Results: PD participants overestimated their cognitive 
abilities in comparison to the control group. Comparisons between unawareness 
measures were not significant. PD participants were more accurate at estimating their 
motor abilities and a significant correlation was found between level of cognitive 
unawareness and caregiver burden. Conclusion: This is the first study to show that 
people with PD tend to over-estimate their cognitive abilities. Results from the 
percentile method could provide an alternative, more direct measure of assessing 
explicit processes related to unawareness in PD. PD patients may be differentially aware 
of deficits within and across various domains of functioning. Our preliminary data from 
carers suggests that unawareness of cognitive abilities is a correlate of caregiver burden.  
 
Keywords: Unawareness, Cognitive abilities, Parkinson’s disease, Motor abilities, 
Caregiver Burden. 
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Introduction 
 
‘Anosognosia’ was first introduced by Babinski (1914; cited in Klinowski & Paulsen, 
2013) to describe unawareness of one’s disease or deficit. In this context, the ability to 
be aware has been defined as: ‘a reasonable or realistic perception or appraisal of a 
given aspect of one’s situation, functioning or performance, or the resulting 
implications’ (Clare, Markova, Roth & Morris, 2011, p.936). Research on unawareness 
has shown that this function is commonly compromised in neurological diseases, such 
as dementia (Williamson, et al., 2010). In comparison, disturbances of awareness have 
not been extensively examined in the second most commonly diagnosed degenerative 
neurological condition, Parkinson’s disease (PD).  
 
PD was first described as the ‘Shaking Palsy’ by James Parkinson in 1817 and was 
initially characterized by motor symptoms such as rigidity, tremor of the limbs and 
bradykinesia (Schapira, 2010). However, PD patients may also experience changes in 
non-motor symptoms, such as impairments in attention, memory, executive functioning, 
slowing of mental processing, delayed response time and visuospatial defects (Peto, 
Jenkinson, Fitzpatrick & Greenhail, 1995; Muslimovic, Post, Speelman & Schmand, 
2005). It is estimated that 85% of PD patients exhibit deficits in cognitive functioning at 
various stages of disease progression (McNamara, 2011). Cognitive disturbances in PD 
can be as disabling as the motor symptoms of the disease, typically with attention, 
complex decision making, and mental flexibility affected first (Schapira, 2010).  
 
Several studies have examined PD individual’s level of unawareness in terms of motor 
symptoms (Sitek, et al., 2011a), expressivity (Mikos, et al., 2009) and social deficits 
(Leritz, Loftis, Crucian, Friedman & Bowers, 2004). In contrast, there has been limited 
research into cognitive domains, with only two studies examining awareness of memory 
functioning (Lehrner et al., 2015; Sitek, Soltan, Wieczorek, Robowski & Slawek, 
2011b). There has been no research examining PD patient’s unawareness of cognitive  
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abilities and whether disturbances in cognitive awareness have similar repercussions for 
individuals with PD as those highlighted in dementia literature.  
 
Methods of Assessing Unawareness 
Methods of measuring unawareness have primarily compared questionnaires that ask 
patients about their current abilities and compare these responses to the objective 
perceptions of a close informant. These patient-proxy questionnaires produce a 
discrepancy rating which is then used to measure the patient’s level of unawareness 
(Sherer, Bergloff, Boake, High & Levin, 1998). There are identified limitations with 
patient-proxy measures, such as informant bias (Clare, 2004b). It has been suggested 
that less biased methods should be developed, such as applying discrepancy scorings of 
objective self-ratings to patient’s perceptions of their abilities (Eslinger et al., 
2005).  Eslinger et al (2005) propose that unawareness is a metacognitive process 
comprising of two components of self-prediction and self-monitoring. Self-predictions 
can be defined as awareness of cognitive ability through pre-test, whereby the patient 
derives self-knowledge of abilities, reflection and previous life experience. Self-
monitoring can be thought of as awareness of cognitive performance through post-
testing estimations, where the client judges their actual performance compared to their 
perceived performance. 
 
Williamson et al (2010) devised an unawareness measure whereby dementia patients 
predicted their cognitive performance before and after administering a standardised 
neuropsychological assessment. These predictions were then rated on a percentile scale, 
represented by a normal distribution curve (illustrated in Figure 1). This allowed for 
direct comparison between pre and post estimates of cognitive performance against 
actual performance using the same scale. Several studies from the limited literature on 
unawareness in PD have applied patient-proxy questionnaires (Amanzio, et al. 2010; 
Sitek et al, 2011b). The percentile ranking method devised by Williamson et al (2010) 
has not been applied in the PD population.  
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Figure 1. Bell shaped curve used as reference for pre and post-test performance 
predictions (Williamson et al, 2010, p. 142). 
 
Factors Associated with Level of Unawareness 
Clare, et al., (2012) proposed that a number of non-cognitive factors influence measures 
of unawareness in dementia. For example, psychosocial factors, such as psychological 
denial and mood may be important influences on reduced awareness (Ownsworth, Clare 
& Morris, 2006). Naylor and Clare (2008) state that unawareness may serve as a 
protective function against the threats to identity of self that follow the onset and 
progression of dementia. In regards to the impact of mood on level of unawareness of 
memory functioning, Sitek et al (2011b) found that self-awareness of memory 
functioning was negatively affected by depressive symptoms, as PD patients who 
overestimated their level of memory dysfunction recorded higher depression scores.  
 
 
2d moderate problems, 3d severe problems). Informants
answered the same quest ions. The mean scores for informants
weresubtracted from pat ient scores. Theserat ingswereobtained
in 13 of the pat ients (five with FTD, eight with AD) and infor-
mants familiar with their current and prior funct ioning.
All stat ist ics were calculated using SPSS (SPSS, Chicago)
software (version 12.0).
RESULTS
Subject characteristics
The FTD, AD and control groups did not sig ificant ly differ
with respect to age, sex or years of educat ion (table 1). AD
subjects performed most poorly on the MMSE, while FTD
subjects’ performance was between AD and controls.
Neuropsychological assessment battery prediction and
performance
AD pat ients made the lowest predict ions of their performance,
while FTD subjects predicted that their performance would be
slight ly higher than controls (figure2). Thesamepat tern held for
post-test self-assessment. Differences in pretest predict ion were
not stat ist ically significant across g oups, while post-test
performance predict ions approached stat ist ical significance
(p¼0.057). The increased difference between groups in post-test
est imat ion was due to the fact that AD pat ients downgraded
their est imates slight ly after the task, whereas controls and FTD
pat ients did not .
Both AD and FTD subjects performed significant ly worse
than normal controls on all NABmodules, with theexcept ion of
navigat ion (table2). On average, FTD subjects scored lower than
AD subjects on all modules except memory, but there were no
stat ist ically significant differencesbetween pat ient groups in any
of the domains or in the average across the NAB tasks.
Discrepancy scores
The average pretest and post-test discrepancies were signifi-
cant ly greater in FTD than in AD and controls (figures 3, 4, left
side). The mean pretest discrepancies were 49.0 (6 23.5) in
FTD, 27.2 (6 18.1) in AD and 3.9 (6 16.5) in controls. Post-test
discrepancies were 54.3 (6 17.9) in FTD, 28.3 (6 15.5) in AD,
and 3.0 (6 15.3) in controls. Differencesbetween groupsfor pre-
and post-test discr pancies er significant f r FTD v rsus
controls, AD versus controls and FTD vs AD. Scat ter plots of
individual discrepancy scores within each group (figures 3, 4,
rig t side) revealed no major out liers.
ANCOVA with post-test discrepancy as the dependent vari-
able, diagnosis as the independent variable and mean NAB
percent ile score as a covariate was significant (R2¼0.758) with
significant effects of diagnosis (p¼0.004) and NAB score
(p¼0.002). Post-hoc Bonferroni comparisons revealed that
Figure 1 Bell curve picture used to
help patients predict and estimate their
performance.
Table 1 Subject characteristics
Characteristic
Alzheimer’s
disease
Frontotemporal
dementia
Normal
controls
Age 67.46 10.4 61.56 4.8 64.96 9.4
Male sex 7 8 4
Years of education 16.66 3.3 15.96 2.2 16.96 2.8
Mini-mental status examination 22.56 6.0 26.96 2.6 29.06 1.3*
N or mean6 SD.
*p¼0.018 by ANOVA.
Figure 2 Mean and standard error of the post-test performance
estimates in control, frontotemporal dementia (FTD) and Alzheimer’s
disease (AD) subjects.
142 J Neurol Neurosurg Psychiatry 2010;81:140e 145. doi:10.1136/jnnp.2008.166041
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In terms of biological influences on unawareness, a correlational study has 
demonstrated a significant relationship between the degree of motor impairment and 
cognitive ability in individuals with PD (Murakami, et al., 2013). Amanzio et al’s 
(2010) study of motor awareness suggested a possible link between severity of motor 
impairment and cognitive functioning, with PD patients performing poorer on tests of 
memory when ratings of motor impairment were high. Therefore, suggesting a possible 
link between motor and cognitive functioning, however no comparison was made in 
relation to level of unawareness. 
 
It has also been shown that unawareness of deficit has significant impact on day to day 
functioning of the PD individual and on the affective state of their caregiver (Rosen, 
2011). Due to PD being a degenerative disease, the task of supporting and caring for the 
individual usually falls to a spouse or family member. This can give rise to caregiver 
burden, the physical, mental, and socio-economic problems experienced by the 
caregivers of people with chronic diseases (Martinez-Martin, et al., 2007). Several 
studies have examined the impact of unawareness of motor abilities on caregiver burden 
in carers of individuals with PD. In their sample which included PD patients, Faison, 
Faria and Frank (1999) reported a positive correlation between level of care needed to 
perform activities of daily living and caregiver burden (r = 0.21; small effect) indicating 
that increases in motor deficits were associated with increases in caregiver burden.  
Schrag, Horvis, Morley, Quinn and Jahanshahi (2006) found that self-reported motor 
disability was associated with greater degree of caregiver burden in PD. Presently, no 
study has examined the relationship between unawareness of cognitive abilities in PD 
and caregiver burden.  
 
As no research exists in relation to PD and cognitive unawareness, this study will 
examine whether people with PD are less accurate at estimating their cognitive abilities 
and monitoring their cognitive performance compared to a control of healthy 
participants. Previous research has shown significant association between PD patients 
motor and cognitive abilities and significant relationship between unawareness of motor  
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abilities and caregiver burden. However, no research has examined the relationship 
between unawareness of cognitive abilities and unawareness of motor abilities, or the 
association between cognitive unawareness and caregiver burden. It is hoped the results 
will further our understanding of unawareness of cognitive abilities in PD and what this 
means for patients, carers and clinicians in a practical and functional sense. 
 
Hypotheses 
 
1. a.  The ability to be aware, as reflected by the ability to judge performances, varies 
within populations. It is predicted that PD patients will overestimate their cognitive 
abilities, as measured by discrepancies between estimated and perceived 
performance on neuropsychological tasks, in comparison to the control group.  
 
b.  Does the method of assessing unawareness matter? As percentile measures of 
unawareness have not previously been deployed in PD patients, the relationship 
between percentile scale and questionnaire methods in the PD only group will be 
examined. PD patients who are less accurate at estimating cognitive abilities (pre 
and post-test discrepancies) will also demonstrate unawareness of abilities in 
general as shown through the patient – proxy discrepancy (concurrent validity).  
 
2. Murakami et al.’s (2013) correlational study found a significant relationship 
between the PD participant’s degree of motor impairment and cognitive problems, 
suggesting that deficits in both areas occur simultaneously. However, the difference 
in unawareness of motor and cognitive abilities has not been examined. Due to the 
salient feedback of motor deficits compared to the more discreet presentation of 
cognitive deficits in individuals with PD, it is predicted that self-ratings of their 
cognitive deficits will be less accurate (estimating and monitoring performance), 
than self-ratings of their motor deficits.  
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3. Based on Faison et al.’s (1999) significant correlational study of motor unawareness 
and caregiver burden, it is predicted that greater unawareness of cognitive abilities 
will also correlate with carer burden. This will further our understanding of the 
progressive changes in cognitive ability in individuals with PD and its possible 
implications on caregiver burden. 
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Method 
Ethical Approval 
Ethical approval was obtained from North of Scotland Research Ethics Committee 
(Appendix 2.1 & Appendix 2.2). Management approval for the protocol was granted by 
NHS Highlands Research and Development Department (Appendix 2.3). Participation 
in the study was voluntary and written informed consent was obtained from all 
participants. 
 
Participants 
PD participants were recruited from the NHS Highland Parkinson’s disease Department. 
The inclusion criteria for PD participants: were adults over the age of 18 years, with a 
clinical diagnosis of PD and at disease stages 1 – 3, as specified by the Hoehn & Yahr 
(H&Y) Staging Scale (1967). Through consultations with the PD department it was 
agreed that due to increasing severity of motor control and physical disabilities as PD 
progresses, it was decided to exclude individuals at stages 4 and 5 on the H&Y 
(confinement to bed or wheelchair unless aided). Control participants were recruited 
through an advertisement in local GP surgeries. Exclusion criteria for all participants 
included a history of learning disabilities; current diagnosed psychiatric disorder (e.g. 
depression); current substance misuse disorder; or previous neurological conditions (e.g. 
Traumatic Brain Injury; Stroke).  
 
Measures  
Demographic information was collected from all participants (age, gender, marital 
status, education and occupation). Additional information regarding severity of disease 
and duration of illness for the PD participants was obtained through reviewing medical 
records. 
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Test of Global Cognitive Functioning - Repeatable Battery for Assessment of 
Neuropsychological Status (RBANS) (Randolph, 1998) (all participants) 
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 
was developed for the dual purposes of identifying and characterizing cognitive decline 
in older adults and as a neuropsychological screening battery for younger patients 
(Randolph, 1998).  
 
The RBANS consists of several subtests which assess the cognitive domains of 
Immediate Memory, Visuospatial/Construction, Language, Attention, and Delayed 
Memory. Scaled score norms for individual subtests and total summary score are 
grouped by decade of age for individuals from 20 to 89 years (Beatty, et al., 2003). 
RBANS Index scores demonstrate strong convergent validity with other 
neuropsychological measures and provide clinicians the ability to interpret individual 
subtests and make direct comparisons between subtests. The RBANS has been found to 
be useful in discriminating patterns of cognitive impairment in Parkinson’s disease 
(Ryder, et al., 2002; Beatty et al 2003).  
 
The Awareness Questionnaire (AQ) (Sherer et al, 1998). (PD patients only) 
The AQ consists of 17 items (cognitive – seven items, motor/sensory – four items and 
behavioural/affective – six items). All items ask patients and their informant to rate their 
current level of functional abilities on a Likert scale ranging from 1 (much worse) to 5 
(much better). Informant interviews for each PD participant was completed by the 
Specialist PD Nurse. Discrepancy scores were calculated through subtracting the 
informant ratings from the self-ratings. An overall discrepancy score >20 indicates 
clinically significant impairment of awareness. 
 
The AQ has high reliability and internal consistencies (Sherer, Hart & Todd, 2003). 
Although initially devised as an awareness measure for brain injury, the AQ has been  
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recommended by The Parkinson Evidence Database to Guide Effectiveness (PDEDGE) 
task force (The Rehabilitation Measures Database, 2015). 
 
Test of Global Motor Functioning: Part three - The Movement Disorder Society 
Uniﬁed Parkinson’s disease Rating Scale (MDS-UPDRS) (Goetz, 2008) (PD 
patients only) 
The MDS-UPDRS incorporates both motor and cognitive components and involves a 
self-administered questionnaire, informant interview and clinician judgement. The 
MDS-UPDRS consists of four subscales; 1- Non-motor Experiences of Daily Living; 2 
- Motor Experiences of Daily Living; 3 - Motor Examination; where the client is given 
instructions by the clinician to complete (client section); 4 - Motor Complications. The 
MDS-UPDRS also incorporates the assessment of severity of motor deficits as outlined 
by the Hoehn and Yahr Scale (Stages 1 – 5). 
 
Carer Burden: Zarit Caregiver Burden Inventory (ZCBI) (Carers only) 
The ZCBI (Zarit, Reever & Bach-Peterson, 1980) is used to assess the distress 
experienced by caregivers of elderly or disabled persons. It consists of 22 questions 
which examine the impact of the client’s disability on the caregiver’s physical health, 
emotional well-being, social and financial issues. For each item, caregivers rate how 
often they have felt a suggested feeling or perception on a five-point scale (0 - never to 
4- nearly always). The ZCBI is scored out of 88 with a higher score indicating higher 
perceived caregiver burden. Although, initially devised for use with caregivers of 
dementia patients, the ZCBI has been found to be feasible and acceptability measure for 
evaluating carer burden in PD patients (Martinez-Martin et al, 2007).  
    
Mood State: Hospital Anxiety & Depression Scale (HADS) (all participants) 
The HADS (Zigmond and Snaith, 1983) - consists of 14 items (7 items on Depression 
and 7 items on Anxiety) each rated from 0 to 3 according to severity of difficulty  
DClinPsy 2015 University of Glasgow 
Page | 66 
 
 
experienced. Subscale totals for both Depression and Anxiety are calculated and an 
individual can score between 0 and 21 for either subscale. Scores of 0-7 indicate no 
Depression or Anxiety; scores between 8 – 10 indicate the Borderline presentation of 
Depression or Anxiety and scores of 11 and above indicate Depression or Anxiety.  The 
HADS demonstrates good internal reliability and validity when assessing anxiety and 
depression in patients with PD (Marinus, Leentjens, Visser, Stiggelbout & Van Hilten, 
2002). 
 
Measure of Unawareness of Cognitive/ Motor Abilities - Percentile Scale  
An assessment based on the designs of Williamson et al (2010) and Medin and McLeod 
(in preparation) was used to assess unawareness of abilities. Awareness as measured 
through pre-test predictions and post-test estimations of performance were assessed by 
asking participants to judge their performance based on a percentile scale, prior to and 
after the administration of the RBANS (both experimental and control groups) and the 
MDS-UPDRS (experimental group). 
 
The percentile scale used for ratings was presented to the participant and explained as a 
normal distribution graph (Figure 1). Participants were informed that on a typical task, 
the majority of healthy age-matched peers would perform around the 50th percentile, 
with smaller numbers performing above or below average (as these principles were 
described the corresponding locations on the bell curve were pointed out by the 
researcher). All participants were then presented with a brief standardised description of 
the tests, as stated in the RBANS and MDS-UPDRS manual instructions. Based on the 
description of the task, participants were asked, ‘How well do you think you will 
perform on the (test name)?’ Participants then predicted their level of performance 
relative to the general population using the percentile scale. After completion of each 
test, the bell curve picture was presented again and the participant was asked to estimate 
how well they actually performed compared to general population. The prompt question 
was: ‘Now that you have completed (test name), how well do you think you 
performed?’ Results from performance pre-predictions and post reflections allowed for  
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differences between self-rated and actual performances to be calculated for the 
standardised tests in its entirety.  
 
Procedure 
During routine outpatient appointments, PD participants who were deemed by the PD 
department to be suitable to participate and had the capacity to provide informed 
consent, were informed of the study by their Consultant Geriatrician and/or Specialist 
PD Nurse. Those who expressed interest were provided with an information pack which 
included a patient information sheet (Appendix 2.5) and consent to contact form 
(Appendix 2.4). Once the signed consent to contact form was obtained, the researcher 
then contacted potential participants to provide further information regarding the study 
and answer any questions. Arrangements were then made for the testing session at a 
GP/Hospital closest to the person’s home. In order to allow comparisons of awareness 
of abilities and caregiver burden, 15 of PD participants consented to a significant other 
being approached to complete the Zarit caregiver burden scale.   
 
Administration of measures took an average of ninety minutes for the PD group. Due to 
potential confounding factors of fatigue and energy levels impacting on concentration 
levels and participant performance, all PD participants were given a 15 minute comfort 
break between the administration of the cognitive and motor tests. Administration of 
measures took on average sixty minutes for control group and ten minutes for the 
caregiver burden interview.  
 
Once informed consent was obtained, measures were administered in the following 
order:  
1. Demographic information (gathered from all participants). 
2. HADS (all participants) 
3. The Awareness Questionnaire (PD Patients only)  
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4. Test of Global Cognitive Ability – RBANS (all participants) 
a. Pre-Test prediction of performance score 
b. Post-Test estimation of performance score 
 
BREAK 
 
5. Test of Global Motor Functioning – MDS-UPDRS – Part three (PD Patients only) 
c. Pre-Test prediction of performance score 
d. Post-Test estimation of performance score 
6. The Zarit Caregiver Burden Inventory – (Carer only) 
 
  All PD participants were examined on the ‘on state’ of medication. 
 
Design and Analysis 
This was a cross-sectional study, consisting of between subjects comparison of PD and 
control participants objective self-ratings on pre-test predictions and post-test 
estimations of performance on tests of cognitive abilities. Within subjects comparisons 
compared PD participants’ unawareness of motor and cognitive abilities. Correlations 
were calculated between the two measures of unawareness (percentile versus 
questionnaire) and caregiver burden.  
 
Raw scores for the RBANS were converted into percentiles using the procedures 
outlined in the manual. As the RBANS is norm-referenced, this allowed for a direct 
comparison of participants’ self-ratings of their cognitive abilities and performance. As 
pre and post predictions were based on a percentile scale this allowed for discrepancy 
scores to be calculated by subtracting pre and post scores from actual percentile scores. 
This resulted in pre and post-test prediction discrepancy scores for each of the 12 tests, 
which were then converted into an overall average percentile score, allowing for 
comparisons across domains for each participant. Negative scores indicated an 
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overestimation of abilities and a positive discrepancy score highlighted an 
underestimation of abilities.  
 
Pre and post motor task discrepancy scores were also calculated for the MDS-UPDRS 
using the same method as the RBANS. The researcher was trained by the PD team on 
how to administer the MDS-UPDRS. The MDS-UPDRS part 3 consists of 33 items, all 
scored on a 5 point scale (with 0 being an absence of any impairment to 4 being unable 
to complete motor task due to motor impairment). As stipulated on the testing form, 
administration of the test involved the researcher either describing or demonstrating 
tasks to the PD patient. Immediately after the task was performed by the patient the 
researcher then rated the PD patient’s motor abilities on the five point scale. For 
conversion purposes these scores were reversed in order to reflect more meaningful 
percentile ranks (0%, 25%, 50%, 75%, 100%). Participants could achieve a total score 
out of 132 (100%). In order to calculate an overall actual motor score and subsequent 
percentile ranking, the total of the participants score on the 33 items was divided by 132 
and multiplied by 100.  
                 
Sample Size  
No previous comparable studies exist from which an estimate of expected effect size 
could be obtained. Williamson et al, 2010, applied the same discrepancy method of 
objective self-rating when examining unawareness of cognitive abilities in people with 
Dementia versus healthy controls and found a large effect size (d = 0.79). 
 
As the current study used similar methodology, participants with a neurological 
condition and measures, it is reasonable to assume that the present study will have a 
similar effect size, 0.8. As calculated by G* Power 3.1 (Faul, Erdfelder, Lang, and 
Buchner, 2009) it was estimated that to detect significant differences between groups 
this study would require 21 participants per group (N = 42) to allow for 0.8 power (α = 
0.05, Effect Size (d) = 0.8). 
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Results 
Data Analysis 
Preliminary analyses were carried out to assess the normality of the distribution of data. 
Visual inspection of histograms and QQ plots were used to assess for skewness, kurtosis 
and outliers. Kolmogorov-Smirnov tests were conducted to assess for normality and 
Levene’s test was used to assess for homogeneity of variance. Several variables were 
found to violate these assumptions of normality and were analysed using non-
parametric tests. 
 
Participant Characteristics 
Recruitment was conducted between March 2015 – July 2015. During this time 42 
participants were recruited to the study, 21 met criteria for the PD group and 21 control 
group participants. Independent sample t-test or non-parametric equivalent (Mann 
Whitney U test) and chi-squared tests were used to compare groups on demographic and 
clinical variables. The participant’s characteristics of both groups are detailed in Table 
1.  
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Table 1. Demographic and Clinical Characteristics of Sample 
Characteristic PD (n=21) 
Mean (SD) or 
N(%) 
Healthy Control 
(n=21) 
Mean (SD) or 
N(%) 
t, z or χ² P value 
Gender (Male: Female) 12:9  
 
9:12 χ²=0.857 0.538 
Age (years) 64.33 (8.84) 55.43 (14.11) t=2.44 0.019 
 
PD Duration (years) 5.19 years 
(range: 1 – 13 
years) 
   
 
Hoehn & Yahr Staging 
 
Stage 1- 9 (42.86) 
Stage 2- 9 (42.86) 
Stage 3- 3 (14.28) 
   
Marital Status 
Single, 
Married, 
Divorced/separated 
Widowed 
 
3 (14.3) 
13 (61.9) 
2 (9.5) 
3 (14.3) 
 
5 (23.8) 
15 (71.4) 
1 (4.8) 
0 (0.0) 
 
χ²=3.976 
 
0.278 
Education 
High School 
College 
University 
 
11 (52.4) 
4 (19.0) 
6 (28.6) 
 
11 (52.4) 
7 (33.3) 
3 (14.3) 
 
χ²=1.818 
 
0.438 
Employment Status 
Employed 
Retired 
 
5 (23.8) 
16 (76.2)  
 
14 (66.7) 
7 (33.3) 
 
χ²=7.785 
 
0.012 
Mood  
HADS – Anxiety 
 
6.14 (3.97) 
 
3.86 (2.37) 
 
t=2.261 
 
0.029 
HADS- Depression  4.33 (2.49) 2.09 (2.42) z=-2.909 0.004 
Neuropsychological  
RBANS Total Score 
(percentile) 
 
36.52 (28.16) 
 
69.14 (24.84) 
 
t=-3.981 
 
<0.005 
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As indicated in Table 1, there were no significant differences between groups in relation 
to gender (p>.05) or marital status (p>.05) or education level (p>.05). There was a 
significant group difference on the demographic variable of employment (p<.05). The 
mean age of the PD group was 64.33 years compared to the control group average age 
of 55.43 years, this difference was statistically significant (t(40)=2.44, p=0.019, two-
tailed). Although neither group demonstrated relatively high levels of mood 
disturbance, the PD group had significantly higher scores than the control group on the 
HADS-Anxiety (t(40)= 2.261, p=0.029, two-tailed) and HADS- Depression (Mann 
Whitney U=106.500, z=-2.909, p=0.004, two-tailed). As expected, the PD group had 
significantly lower percentile ranks on the neuropsychological test (RBANS) than the 
control group (t(40)=-3.981, p=<0.005, two-tailed).  
 
Hypothesis 1.a - Are people with PD less accurate at estimating their cognitive abilities 
and monitoring their performance compared to healthy control participants.  
Change in predictions between pre and post estimations of performance for both groups 
were not significant; Pre-test (t(40)=-1.946, p=<0.059, two-tailed, r=0.29) and Post-test 
(z=-1.711, p=0.087, two-tailed, r= -0.26). Table 2. Documents the mean and range of 
percentile ranks of both groups on the RBANS. 
 
Table 2. Mean and range of percentile ranks on the RBANS.  
 RBANS Pre-test 
Predicted Percentile  
Rank   
RBANS Actual 
Performance Percentile  
Rank 
RBANS Post-test 
Estimated Percentile  
Rank  
PD 
Mean (SD) 
Range 
 
51.9 (13.06) 
24.25 – 74.50 
 
36.52 (28.16) 
1.00 – 94.00 
 
60.59 (16.38) 
31.75 – 87.25 
Healthy Controls 
Mean (SD) 
Range 
 
60.38 (16.07) 
20.25 – 89.65 
 
69.14 (24.84) 
9.00 – 98.00 
 
69.69 (15.67) 
28.70 – 94.70 
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Discrepancy scores  
PD participants overestimated their cognitive abilities both when estimating their pre 
and post cognitive performance. Although control participants initially underestimated 
their abilities, their post-performance estimations were almost identical to their actual 
percentile rank performance. The average pre-test and post-test prediction discrepancies 
were significantly greater in PD than in controls; pre-test discrepancy measuring 
unawareness of cognitive performance (z= - 3.031, p= 0.002, r= -0.47) and post-test 
discrepancies measuring unawareness of cognitive monitoring (z= - 3.157, p= 0.002, r= 
-0.49). Overall, PD participants were less aware of their cognitive abilities and had 
poorer monitoring ability than control participants. Table 3 shows means and standard 
deviations, of pre and post discrepancy percentile ranks for both groups. Figure 2 
displays the pre and post discrepancies between the groups self-estimates of cognitive 
functioning and neuropsychological test performance using percentile rank of test 
scores. 
 
Table 3. Mean (SD) and range of pre and post discrepancy percentile ranks for 
cognitive abilities for both groups. 
  Cognitive Pre-test 
Prediction Discrepancy 
Percentile  Rank 
Cognitive Post-test 
Prediction Discrepancy 
Percentile  Rank 
PD 
Mean (SD) 
Range 
 
-15.06* (22.30) 
-49.00* – 33.35 
 
-24.07* (22.75) 
-58.25* – 24.60 
Healthy Controls 
Mean (SD) 
Range 
 
8.76 (25.90) 
-65.75* – 47.00 
 
-0.55* (21.03) 
-62.00* – 38.25 
*Note: negative figures represent an overestimation and positive figures represent an 
underestimation of cognitive abilities.  
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    Pre-test estimate   /  Post-test estimate 
 
Figure 2. Unawareness discrepancies of self-estimates (pre and post-performance) and 
neuropsychological test performance using percentile rank of test scores. 
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Hypothesis 1.b.  Does the method of assessing unawareness matter? Examine PD 
participant’s general unawareness of deficit.  
An analysis was calculated between the two methods of measuring unawareness of 
abilities in PD (percentile scale and questionnaire). Through the application of the 
Awareness Questionnaire (AQ) a general unawareness of deficit score was obtained for 
all PD participants. All 21 PD participants rated their general level of abilities 
(cognitive, motor and affective) to be poorer than before their PD diagnosis. Through 
discrepancy scores between self-rated and objective ratings completed by a clinician, no 
participant reached the >20 threshold of clinically significant impairment of awareness 
on the AQ (Mean= 0.81, SD = 4.77, range= -7 to 10). Table 4 shows means and 
standard deviations, of AQ discrepancy scores (Total and Cognitive Sub-Scale).  
 
Table 4 Means (SD) and range of Awareness Questionnaire discrepancy scores (Total 
and Cognitive Sub-Scale) for PD participants.  
 Awareness Questionnaire 
Total Discrepancy Score 
Awareness Questionnaire 
Cognitive Sub-Scale 
Discrepancy Score 
PD 
Mean (SD) 
Range 
 
1.48 (4.60) 
-7.00 – 10.00 
 
0.89 (2.71) 
-5.00 – 8.00 
  
 
The hypothesis that unawareness of cognitive abilities, as measured by percentile 
predictions of cognitive performance would be correlated with total score of AQ was 
not supported for pre-test (rho = -.23, p > .05) or post-test discrepancies (rho= -.065, 
p>.05). Further analysis of the relationships between AQ cognitive sub-scale with pre-
test discrepancy (rho = -.25, p > .05) and post-test discrepancy (rho= .011, p>.05) were 
not significant.  
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Hypothesis 2 - PD participants will be less accurate at estimating their pre and post-
performance on tasks of cognitive abilities than tasks of motor abilities. 
 
Within subject comparison of change in predictions of pre–test estimations of 
performance for cognitive versus motor abilities was found to be significant (t(20)=-
4.923, p=<0.05, two-tailed, r=0.74). However, change in predictions of post-test 
predictions between cognitive and motor abilities was not statistically significant 
(t(20)=-2.063, p=0.052, two-tailed, r=0.42). 
 
Discrepancy scores  
PD participants overestimated their cognitive abilities at both the pre and post ratings of 
cognitive performance. In comparison, they underestimated their motor abilities at both 
the pre and post performance time-points. The within groups differences in pre-test and 
post-test prediction discrepancies were significantly greater for cognitive abilities than 
motor abilities; unawareness of performance pre-test (z= - 2.972, p= 0.002, r= -0.46) 
and post-test (t(20)=-5.254, p=<0.05, two-tailed, r=0.76). Overall, PD participants were 
less aware and had poorer monitoring of their cognitive abilities than their motor 
abilities. The RBANS discrepancy scores in Table 3 and Table 5 outline the mean and 
standard deviations of percentile ranks predictions and actual score on the MDS-
UPDRS, alongside pre and post discrepancy percentiles for PD participants. These 
results suggest that PD participants were more accurate in estimating pre and post-test 
performance of their motor abilities than their cognitive abilities. Figure 3 demonstrates 
the difference in the PD group’s discrepancies between their actual performance and pre 
and post estimations of cognitive and motor abilities.  
 
 
 
 
DClinPsy 2015 University of Glasgow 
Page | 77 
 
 
 
Table 5. Mean, standard deviations and range of percentile ranks on the MDS-UPDRS.  
 MDS-UPDRS 
Pre-test 
Prediction 
Percentile  Rank 
MDS-UPDRS 
actual 
performance 
Percentile  Rank 
MDS-UPDRS 
Post-test 
estimation 
Percentile  Rank 
Motor Pre-test 
Prediction 
Discrepancy 
Percentile  Rank 
Motor Post-test 
Prediction 
Discrepancy 
Percentile  Rank 
PD 
Mean 
(SD) 
Range 
 
67.44  
(17.51) 
35.88–93.24 
 
71.93  
(16.11) 
36.47– 96.47 
 
 
68.06  
(19.14) 
33.24– 95.29 
 
 
4.49  
(5.27) 
-4.12– 15.88 
 
3.87  
(6.36) 
-5.89– 18.52 
 
 
  Pre-test estimate       /     Post-test estimate  
Figure 3. Unawareness of PD patient’s discrepancies of pre and post-test estimations 
and actual test performance of cognitive and motor functioning using percentile ranks of 
standardisation test scores. 
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Hypothesis 3 – Zarit Burden Interview: greater unawareness of cognitive abilities will 
be correlated with carer burden 
Zarit Burden Interviews were obtained from the significant other of 15 PD participants 
(13 - Spouses, 1 – Sibling and 1 – Daughter).  Caregiver burden was rated by the 
significant other as; ‘little or no burden’ = 9, ‘mild to moderate burden’ = 5 and 
‘moderate to severe burden’= 1 (Mean =17.20, SD=13.32, range= 4 – 45).  
 
The correlation between ratings of caregiver burden and level of cognitive unawareness 
(pre-test and post-test estimations) were examined. As several of the cognitive measures 
were not-normally distributed, non-parametric Spearman’s rho correlations were 
conducted to explore the associations between caregiver burden with level of cognitive 
unawareness. Table 6 presents the correlation data examining the associations between 
ratings of caregiver burden and measures of cognitive abilities.  
 
Table 6 Bivariate Spearman’s rho correlations between caregiver burden and level of 
unawareness of cognitive abilities (pre and post-test estimations). 
 Level of cognitive unawareness – 
Pre-test estimations. 
Level of cognitive unawareness- 
Post-test estimations. 
Zarit Caregiver Burden -0.728** -0.744** 
** Significant at p <0.01 
 
In line with the hypothesis that caregiver burden would be associated with unawareness 
of cognitive abilities, caregiver burden scores were significantly negatively correlated 
with level of cognitive unawareness, pre-test (p < .01) and post-test (p < .01). Therefore 
suggesting that an increase in carer burden was associated with unawareness of 
cognitive abilities, both in terms of pre and post-test estimations of performance.  
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Discussion 
 
Are people with PD less accurate at estimating their cognitive abilities and 
monitoring their performance compared to healthy control participants?  
 
The aim of the current study was to examine unawareness of cognitive abilities in a 
clinical sample of adults with PD. Although the groups differed in age, the age-
standardised nature of the RBANS means that scores were age adjusted, which allowed 
for valid performance comparisons between groups. As hypothesised, PD participants 
were significantly less accurate at predicting their cognitive abilities and monitoring 
their performance compared to a control group of healthy participants. The participants 
with PD overestimated their cognitive abilities and performance on neuropsychological 
tests by 15-24%. In comparison, control participants initially underestimated their 
abilities by 9%, but were able to adjust their post-performance judgements to an almost 
identical percentile rank to that of their actual performance, over-estimating their 
cognitive performance by only 0.55%. These between group differences in pre and post 
percentile rank discrepancies, are comparable to studies which have applied similar 
methods to smaller samples of people with dementia (Williamson et al, 2010) and 
schizophrenia (Medin & McLeod, in.prep).  
 
As this was the first study to assess unawareness of cognitive abilities in PD, it is 
difficult to draw comparisons to the limited knowledge base of unawareness in PD. Our 
results are inconsistent with the findings using patient-proxy discrepancies of memory 
functioning in PD, which observed relatively accurate self-appraisals of memory 
functioning in PD participants (Lehrner et al, 2015 & Sitek et al, 2011b). However, 
methodological limitations of previous research included lack of a control group (Sitek 
et al, 2011b). Clare, Whitaker & Nelis (2010) stated that it is unclear how much of the 
over-under estimation reported by people with neurological conditions was within the 
normal range and to what extent inaccuracy of ratings is a particular feature of the 
condition, rather than simply a reflection of the normal ageing process.  Dunning,  
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Meyerowitz & Holzberg, (1989) state that when people (general population) are asked 
to estimate their abilities, the judgements they provide tend to be self-serving, usually 
resulting in an over-estimation.  
 
These self-serving appraisals can take several biased forms. Miller and Ross (1975) 
outlined that people either self-protect, by underestimating their abilities or self-enhance 
through overestimation. Through comparisons with a control group we have found that 
PD participants less accurately judged their cognitive abilities and monitoring of 
performance. PD patients displayed inflated self-appraisals, as they tended to 
overestimate their cognitive abilities and performance. Whereas, healthy controls 
initially underestimated their abilities in a self-protecting way and were then able to 
accurately adjust their estimations through self-monitoring of performance. These 
findings are similar to Oyebode, Telling, Hardy and Austin (2007) who examined 
dementia patients estimations of unawareness compared to two control groups; young 
and older healthy volunteers. Results from their analysis also found a self-serving bias, 
with the dementia group overestimating, younger volunteers underestimating and the 
older group accurately predicting abilities. Due to the significant difference in age 
between our groups this may account for the initial underestimation found in our 
healthy volunteers. 
 
Does the method of assessing unawareness matter? PD participant’s general 
unawareness of deficit. 
Results from the Awareness Questionnaire, suggested that none of our PD sample 
reached the clinical threshold of impairment of awareness in general or in the sub-
domain of cognitive abilities. This is consistent with previous research findings in 
patient-proxy discrepancies, which have observed relatively accurate self-appraisals of 
memory functioning in PD participants (Lehrner et al., 2015; Sitek et al., 2011b). 
However, no association between the AQ and percentile estimates of performance 
methods was found in our PD sample, unlike Williamson et al. (2010) who found a  
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significant relationship between percentile based and questionnaire measures of 
unawareness.  
 
This leads us to question the concurrent validity of the percentile based approach on 
measuring unawareness of abilities in PD. Williamson et al (2010) suggested that a 
potential limitation of the percentile measure was that it may reflect individual’s deficits 
in estimation ability rather than awareness. However, Appollonio, et al., (2003) 
examined PD patient’s estimation ability on several tests (Cognitive Estimation Task 
and The Time and Weight Estimation test). Results did not show a significant deficit of 
cognitive estimation ability, suggesting that PD patients do not show general problems 
with estimation. In relation to our findings, the non-significant difference of pre and 
post percentile predictions between the PD and control groups, suggests that both 
groups had interpreted the instructions regarding the percentile ranks correctly. In 
regards to the discrepancy scores, our finding that PD patient were more accurate with 
estimations of their motor abilities, suggests that there was not a general problem with 
ability estimation in our PD sample.  
 
The findings from our study demonstrate that the questionnaire method of measuring 
unawareness has not detected the significant effects of the percentile based analysis. 
This may be due to measures assessing different components of awareness. Awareness 
of deficit is a dimensional construct comprising of a level of explicit and implicit 
awareness of functioning (Clare, 2004b). Explicit awareness is where the individual has 
the ability to verbally acknowledge their abilities, this may be influenced by social 
pressures and defensiveness (Oyebode et al, 2007). Implicit awareness is defined as 
when an individual has the ability to accurately judge the impact of their cognitive 
deficits and are able to modify their behaviours/actions accordingly. (Medin & McLeod, 
in.prep). Findings from our study may suggest that when completing the AQ measure, 
PD patients were more accurate, therefore more aware of their cognitive abilities. 
However, performance on the percentile measure suggested unawareness in our PD 
sample. This may suggest that PD patients in our sample, showed differential awareness 
within cognitive domains. Although they explicitly denied their cognitive deficits, as  
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measured through the percentile estimations, they were unintentionally processing 
components of their deficit implicitly through results of the AQ. 
 
Are people with PD less accurate at estimating and monitoring their performance on 
tasks of cognitive abilities than tasks of motor abilities?  
 
PD participants were significantly less accurate at estimating and self-monitoring their 
performance for cognitive abilities compared to motor abilities. Findings from our study 
suggested that PD patients tended to overestimate their pre and post-test performance of 
cognitive abilities. In comparison, although slightly under-estimated, predictions of 
their motor abilities were more accurate, with less discrepancy between self-ratings and 
actual performance. This is consistent with previous findings of motor awareness, which 
suggested that PD patient’s provided accurate judgements of disability similar to those 
of observer ratings (Brown et al.’s, 1989 & Sitek et al, 2011a). Several studies have 
shown a link between severity of motor impairment and cognitive problems in PD with 
deficits occurring simultaneously (Murakami et al.’s, 2013; Amanzio et al, 2010). In 
term of unawareness, our study has found a difference between PD patients degree of 
motor and cognitive unawareness. This might suggest that awareness and self-
monitoring are not part of a unitary ability, but may be dissociable capacities that are 
domain specific. 
 
The effect of unawareness of cognitive abilities on carer burden. 
Although, several studies have shown an association between unawareness of motor 
abilities and caregiver burden in PD, no previous literature exists in regards to 
unawareness of cognitive abilities. As expected, increased caregiver burden was 
correlated with unawareness of cognitive abilities, both in terms of predicting awareness 
and self-monitoring of performance. Our results suggest that PD patients who are 
unaware of their cognitive deficits seem to place greater burden on their carers. Previous 
literature highlighted a weak effect between awareness of motor deficits in PD and 
caregiver burden (Faison et al, 1999). In comparison, our sample demonstrated a strong 
association between cognitive awareness and caregiver burden. The potential  
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confounding factors of severity/duration of PD must be taken into account when 
discussing caregiver burden. Research with other dementia sufferers suggests that 
caregiver burden increases with increasing severity of illness (Mioshi et al, 2013). It is 
not possible to determine from our analysis whether individuals who exhibited greater 
unawareness of cognitive abilities were at a mild or moderate stage of disease severity 
or whether they had experienced a longer duration of PD. The impact of these variables 
should be examined in future studies.  
 
Clinical Implications 
Through the use of a percentile based approach, it was shown that PD individual’s 
cognitive awareness was significantly poorer than the control group, as measured 
through predictions of pre and post- test performance. In comparison, between domains 
of functioning it was shown the PD patients were less accurate in their judgements of 
their own cognitive abilities compared to their motor abilities. These significant 
differences may have important implications for clinicians working with this population 
in terms of assessment and understanding of unawareness of deficits in PD.  
 
The phenomenon of unawareness involves an inadequate evaluation of one’s 
impairments (Clare, 2004a). Previous research in dementia suggested that unawareness 
of abilities could have serious implications for the individual, as it was found that 
people with dementia who overestimated their abilities were less likely to adhere to 
treatment and more likely to expose themselves to unnecessary risk. Individuals who 
underestimated their abilities were more likely to unnecessarily limit their activities and 
avoid situations they perceived as challenging (Clare et al, 2010). All these factors may 
be relevant to the PD population, as prevalence of dementia associated with PD (PDD) 
is estimated to be six times greater than in the general population (Kulisevsky & 
Pagonabarraga, 2009) and cognitive disturbances are common in PD at various stages of 
disease progression (Schapira, 2010). Findings from the differences between the 
domains of cognitive and motor deficits, highlights the importance of cognitive deficits 
in PD, which may be less salient than the motor symptoms. This may have implications  
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for clinicians in spotting early warning signs and detecting changes in less salient 
cognitive abilities.  
 
At present, unawareness research is heavily reliant on using questionnaires to ascertain 
discrepancies between patient’s subjective ratings and informant ratings of functioning. 
As shown in this study, no difference was found between patient-proxy ratings. 
However, through examining unawareness through judgments of ability based on 
percentiles, a significant difference was found between PD patient’s ability to predict 
and monitor their cognitive abilities. This leads us to question whether current ways of 
assessing unawareness of cognitive deficits are insufficiently sensitive. As self-appraisal 
is reliant on explicit awareness, where the individual is able to verbally acknowledge 
their deficits, our results suggest that PD individuals may under-report cognitive 
difficulties. Employing a percentile based measure may remove the inherent perspective 
bias from confounding results obtained from patient-proxy discrepancy scores (Sitek et 
al, 2011b) and may expose different aspects of awareness  (Medin & McLeod, in.prep). 
 
The significant correlation between unawareness of cognitive abilities and Caregiver 
Burden, highlights the wider systemic impact of neurological conditions. 
Implementation of compensatory strategies (to reduce the impact of deficits on 
everyday functioning) is dependent on accurate appraisal of one’s cognitive abilities 
(Clare, 2004b). Therefore unawareness may mean the PD patient is more likely to 
engage in behaviour that is beyond their abilities, which in turn increases caregiver 
burden (Faison et al, 1999). In conclusion, unawareness of cognitive abilities in PD may 
have several real life implications for the individual with PD, clinicians and carers.  
 
Strengths and Limitations of Study 
This is the first study to examine unawareness of cognitive abilities in PD, results have 
highlighted areas which need further exploration: differences between cognitive 
unawareness in PD patients and healthy volunteers, differential unawareness on domain  
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functioning in PD, impact on caregiver burden and clinical implications in methods of 
measuring unawareness. Other strengths of this study were that the majority of 
measures used have previously been administered on individuals with PD and 
demonstrate good psychometric properties and that the calculated sample size was 
achieved.  
 
The results of the study must be considered in the context of several limitations.  A 
significant difference was shown in the affect of the groups, with PD participants 
scoring significantly higher in depression and anxiety in the HADS. However, neither 
group included participants who reached the clinical threshold of >11 for depression. 
Within our PD sample the level of affective disturbance does not seem to explain an 
alternative explanation for the unawareness scores obtained, e.g. the overestimation of 
results are due to the presence of mild depressive symptoms (Sitek et al, 2011b).  
 
Due to ethical reasons, PD participants were initially contacted by a member of the PD 
department during their routine outpatient appointment, this may have led to self-
selection bias of the clinical team informing participants they felt would be more likely 
to engage in the research. A further limitation was that members of the PD department 
who acted as informant raters for AQ were not blind to hypotheses and this could have 
influenced objective ratings. Therefore, the samples in this study may not be an accurate 
representation of the clinical PD population. 
 
Future Research 
There is a need to replicate these findings, as further research exploring cognitive 
unawareness in this clinical population is needed. The results of this study apply mostly 
to PD patients with mild to moderate severity of disease, as measured by the Hoehn and 
Yahr staging scale. Due to the degenerative nature of PD, individuals progress through 
the Hoehn & Yahr stages at various rates. Although this study did not differentiate 
between individuals at stages 1, 2 and 3, it would be clinically and individually  
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beneficial to differentiate between the various stages of PD, in order to best facilitate the 
individual with PD and their care givers as they transition through the disease. The 
generalisability of the current findings to individuals in the later stages of the disease is 
also limited. In regards to dementia, Ecklund-Johnson & Torres (2005) state that 
awareness is a common clinical symptom at the earliest stages of the disease and that 
the frequency of unawareness increase with disease progression. Future research should 
consider the advantages of using a large, longitudinal research design examining the 
long-term impact of unawareness of cognitive abilities with increasing PD severity. 
 
Further research is required to explore other variables in relation to unawareness of 
cognitive abilities in PD. Due to previous research stating that depression may impact 
on level of unawareness in PD, all individuals who met criteria for major depression 
were excluded from our study. Although anxiety was not deemed to be a mediating 
factor of unawareness in our study design, results from the HADS suggested that PD 
individuals were more likely rate their level of anxiety higher than control participants. 
Further research is needed to investigate the non-cognitive influencing factor of anxiety 
on level of unawareness. 
 
As limited research has been conducted in this area of PD, it is uncertain whether these 
biopsychosocial factors of disease severity and anxiety have differing influences on PD 
individual’s level of unawareness of their cognitive abilities. In order to examine these 
possible relationships, methodological limitations of this study must be taken into 
consideration when examining unawareness of cognitive abilities in PD. 
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Conclusion 
The key findings of this study indicate that PD participants show unawareness of 
cognitive abilities relative to healthy controls, with PD individuals having a tendency to 
overestimate their abilities. Unawareness of cognitive abilities measured by percentile 
rank was not significantly associated with the standardised measure of the Awareness 
Questionnaire. Results may suggest that the percentile method could provide an 
alternative, more direct measure of assessing explicit processes related to unawareness 
in PD. Further comparisons across the domains of cognitive and motor abilities 
suggested that PD participants had greater unawareness on tasks examining their 
cognitive abilities. These results may suggest that PD individuals can be differentially 
aware of deficits within and across various domains of functioning. Finally, a 
significant correlation was found between level of cognitive unawareness and caregiver 
burden. These results highlight the need to detect and address unawareness in order to 
reduce carer burden. 
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Abstract 
This reflective account described the importance of clinical supervision on my personal 
and professional development over the course of training. This account was structured 
using the Integrated Developmental Model (Stoltenberg, McNeill, and Delworth, 1998) 
and Gibbs’ Model of Reflection (1988). This was done through charting different 
learning experiences of supervision and the impact it had on the development of my 
clinical skills and confidence in applying psychological methods and concepts, namely 
the unique skill of formulation. In doing so, I identified the thoughts and feelings I 
experienced during these learning experiences and evaluated these in the context of my 
development as a competent and confident clinician. This account also considered the 
ever changing political landscape and discussed the impact that governmental policies 
and guidelines had on the diverse and extended role of a clinical psychologist. 
Throughout the account I reflected on what this will mean for my future development 
and clinical practice when I become a qualified Clinical Psychologist. 
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Abstract 
This reflective account charts the various research experiences I have had throughout 
my Doctoral training in Clinical Psychology and reflects on my experiences as an 
evolving scientist practitioner. Through the application of Rolfe, Freshwater and 
Jasper’s (2001) model of reflection, this account documents three of my key research 
learning situations. First I reflect on the service-based evaluation project I completed in 
my first year. In this section I discuss the shift in attitude I had from initial trepidation 
of conducting an audit, to my greater appreciation of the clinical and service 
implications that can be brought about through service evaluation. I then reflect on my 
biggest research challenge to date, my Major Research Project (MRP). I then discuss the 
wider role of being a scientist practitioner, and reflect on the valuable application of 
routine outcome monitoring, which has the dual role of both informing clinical practice 
and service development.  As I reflect on the differing roles of a scientist practitioner, I 
discuss the purpose and benefits of clinician-led research. I conclude with a reflection 
about the challenges that currently face qualified Clinical Psychologists and discuss the 
wider implications of being a scientist practitioner. 
 
Reflecting on my research experiences throughout training has enabled me to explore 
and make sense of my learning, actions and reactions. These invaluable research skills 
have equipped me with a new found passion for conducting research and I look forward 
to transferring these skills to my new role as a post-qualified Clinical Psychologist. 
Being a scientist practitioner really is at the heart of every Clinical Psychologist. 
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Appendix 1.1: Author Guidelines Neuropsychological Rehabilitation:  
             An International   Journal 
 
1. Journal-specific guidelines 
 This journal accepts original (regular) articles, scholarly reviews, and book reviews. 
  The style and format of the typescripts should conform to the specifications given in 
the Publication Manual of the American Psychological Association (6th ed.). 
   There is no word limit for manuscripts submitted to this journal. Authors should 
include a word count with their manuscript.  
2. General guidelines 
 Manuscripts are accepted in English. Oxford English Dictionary spelling and 
punctuation are preferred. Please use double quotation marks, except where “a 
quotation is ‘within’ a quotation”. Long quotations of words or more should be 
indented without quotation marks. 
 Manuscripts should be compiled in the following order: title page; abstract; 
keywords; main text; acknowledgements; references; appendices (as appropriate); 
table(s) with caption(s) (on individual pages); figure caption(s) (as a list). 
 Abstracts of 150-200 words are required for all manuscripts submitted. 
 Each manuscript should have up to 5 keywords. 
 Search engine optimization (SEO) is a means of making your article more visible to 
anyone who might be looking for it. Please consult our guidance here. 
 Section headings should be concise. 
 All authors of a manuscript should include their full names, affiliations, postal 
addresses, telephone numbers and email addresses on the cover page of the 
manuscript. One author should be identified as the corresponding author. Please give 
the affiliation where the research was conducted. If any of the named co-authors 
moves affiliation during the peer review process, the new affiliation can be given as 
a footnote. Please note that no changes to affiliation can be made after the 
manuscript is accepted. Please note that the email address of the corresponding 
author will normally be displayed in the article PDF (depending on the journal style) 
and the online article. 
 All persons who have a reasonable claim to authorship must be named in the 
manuscript as co-authors; the corresponding author must be authorized by all co-
authors to act as an agent on their behalf in all matters pertaining to publication of 
the manuscript, and the order of names should be agreed by all authors. 
 Biographical notes on contributors are not required for this journal. 
 Please supply all details required by any funding and grant-awarding bodies as an 
Acknowledgement on the title page of the manuscript, in a separate paragraph, as 
follows: 
 For single agency grants: "This work was supported by the [Funding Agency] 
under Grant [number xxxx]." 
 For multiple agency grants: "This work was supported by the [Funding Agency 
1] under Grant [number xxxx]; [Funding Agency 2] under Grant [number xxxx]; 
and [Funding Agency 3] under Grant [number xxxx]." 
 Authors must also incorporate a Disclosure Statement which will acknowledge 
any financial interest or benefit they have arising from the direct applications of 
their research. 
 For all manuscripts non-discriminatory language is mandatory. Sexist or racist 
terms must not be used. 
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 Authors must adhere to SI units. Units are not italicised. 
 When using a word which is or is asserted to be a proprietary term or trade 
mark, authors must use the symbol ® or TM. 
2. Style guidelines 
 Description of the Journal’s reference style. 
 Guide to using mathematical scripts and equations. 
 Word templates are available for this journal. If you are not able to use the template 
via the links or if you have any other template queries, please 
contact authortemplate@tandf.co.uk. 
 Authors must not embed equations or image files within their manuscript 
3. Figures 
 Please provide the highest quality figure format possible. Please be sure that all 
imported scanned material is scanned at the appropriate resolution: 1200 dpi for line 
art, 600 dpi for grayscale and 300 dpi for colour. 
 Figures must be saved separate to text. Please do not embed figures in the 
manuscript file. 
 Files should be saved as one of the following formats: TIFF (tagged image file 
format), PostScript or EPS (encapsulated PostScript), and should contain all the 
necessary font information and the source file of the application (e.g. 
CorelDraw/Mac, CorelDraw/PC). 
 All figures must be numbered in the order in which they appear in the manuscript 
(e.g. Figure 1, Figure 2). In multi-part figures, each part should be labelled (e.g. 
Figure 1(a), Figure 1(b)). 
 Figure captions must be saved separately, as part of the file containing the complete 
text of the manuscript, and numbered correspondingly. 
 The filename for a graphic should be descriptive of the graphic, e.g. Figure1, 
Figure2a. 
 
Last updated 11/03/2014 
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Appendix 1.2: Data Extraction Form 
 
Citation 
Lead Author  
 
Year Published  
 
Title  
 
Journal  
 
Country of 
Origin 
 
 
Type of Study 
 
 
 
Screening and Selection: 
Were participants diagnosed with Parkinson’s disease? YES / NO 
Did the study report standardised measure of PD?  YES / NO 
Were participants of the pre-specified age?   YES / NO 
Did the study report standardised measure of Depression? YES / NO 
Did the study report on Risk factors/descriptive features associated Depression in PD?
 YES / NO 
     OR 
Did the study report on the association between Awareness and Depression in PD? 
 YES / NO 
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Notes / Short description of Study: 
 
 
FINAL DECISION   INCLUDED  /   EXCLUDED 
 
 
REASONS FOR EXCLUSION OF STUDY FROM REVIEW:  
Patients:  
Different disease (Neurological disease   / Mental Health Disorder) 
Different Age.       
Outcomes:  
No clinically relevant outcomes assessed    
 Preliminary Date 
 Qualitative data. 
Other:   
Duplicate publication      /       Book Review    /   Conference abstract   /   
Poster Presentation    /    Language    / Thesis 
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INCLUDED STUDIES – DATA EXTRACTION. 
Study Characteristics. 
 
Study aims / purpose: 
 
 
What are the eligibility criteria?  
Inclusion: 
 
 
Exclusion: 
 
 
Participant characteristics  
Age Range   
Mean Age   
Gender   
Age of Onset   
Disease stage/severity    
 
Recruitment  
How were participants recruited? 
 Convenience sample  / Geographic cohort  / Highly selective 
sample 
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Number of participants recruited? 
 
Was there a control group?  Yes /  NO 
If Yes, what were control groups characteristics: 
 
How were participants recruited in Control group? 
Convenience sample  /    Geographic cohort   / Highly selective 
sample 
Risk factors and/or descriptive features associated with Depression in PD? 
Clinical Factors Severity of PD  
 Age of Onset  
 Stage of Disease  
 Duration of illness  
 Premorbid psychiatric 
Condition 
 
Behavioural Factors Apathy  
 Motivation  
 Social Withdrawal  
Physiological Factors Sleep Disturbance  
 Fatigue  
Cognitive Factors Awareness  
 Cognitive impairment: 
Memory problems 
 
Motor Factors Balance/Falls  
 Dyskinesia  
 Bradykinesia   
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Outcome Measures: 
Standardised Measure of PD Severity 
 
 
Standardised Measure of Depression 
 
 
Other Standardised Measures;  Awareness 
 
 
Other Standardised Measures;  Cognitive 
 
 
Other Standardised Measures;  Motor 
 
 
Other Standardised Measures;   
 
 
 
 Data Analysis  
Type of analysis? 
 
Conclusion 
 
 
Awareness and Depression in PD. 
 
Type of analysis? 
 
Strength of Association between Awareness and PD: 
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Conclusion 
 
Factors associated with Depression and Awareness in PD: 
 
 
Methodological Quality of Paper -  Crowe Critical Appraisal Tools (CCAT – 
Maximum score of 40 = 100%) 
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Appendix 1.3 Quality Ratings for Included Studies 
Study Preliminaries  Intro Design Sampling Data 
Collection 
Ethical 
Matters  
Results  Discussion Overall Quality Rating 
Total  % 
 
Amanzio, Monteverdi, Giordano, Soliveri, 
Filippi & Geminani, (2010)  
4 5 3 3 4 3 3 4 29 73 
 
Brown, MacCarthy, Jahanshahi & Marsden 
(1989)  
3 5 3 4 5 0 5 4 29 73 
 
Farabaugh, Locascio, Yap, Weintraub, 
McDonald, Agoston, Alpert, Growdon & 
Fava (2009) 
5 5 3 3 4 1 4 4 29 73 
 
Lehrner, Kogler, Lamm, Moser, Klug, 
Pusswald, Dal-Bianco, Pirker & Auff 
(2015) 
5 5 3 5 3 3 3 4 31 78 
 
Saez-Francas, Hernandez- Vara, Roso, 
Martin & Brugue (2013) 
4 5 3 4 4 2 4 4 30 75 
 
Schrag, Jahanshahi Quinn (2001) 5 5 3 4 4 1 4 3 29 73 
 
Sitek, Soltan, Wieczorek, Schinwelski, 
Robowski, Reilmann, Guzinska, Harciarek, 
Krysa & Slawek (2011a) 
5 3 3 4 3 2 3 4 27 68 
 
Sitek, Soltan, Wieczorek, Robowski & 
Slawek (2011b)  
5 5 3 4 3 3 3 4 30 75 
 
Verbaan, Marinus, Visser, van Rooden, 
Stiggelbout & van Hilten (2007) 
5  5 4 4 3 0 4 3 28 70 
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Appendix 2.1: Author Guidelines Journal of Neurology, Neurosurgery and 
Psychiatry     
Preparing your manuscript 
All material submitted is assumed to be submitted exclusively to the journal unless 
otherwise stated. Submissions may be returned to the author for amendment if presented 
in the incorrect format. 
 
Manuscript documents are deleted from our systems 6 months after completion of the 
peer review process. 
Cover letter 
Your cover letter should inform the Editor of any special considerations regarding your 
submission, including but not limited to: 
 Details of related papers by the same author(s) already published or under 
consideration for publication. 
 Details of previous reviews of the submitted article. 
Copies of related papers, previous Editors’ and reviewers' comments, and responses to 
those comments can be submitted using the File Designation "Supplementary file for 
Editors only". Editors encourage authors to submit previous communications as doing 
so is likely to expedite the review process. 
NIH Employees 
Manuscripts authored or co-authored by one or more NIH employees must be submitted 
with a completed and signed NIH Publishing Agreement and Manuscript Cover 
Sheet according to NIH’s Employee Procedures. 
Title page 
The title page must contain the following information: 
 Title of the article. 
 Full name, postal address, e-mail and telephone number of the corresponding author. 
 Full name, department, institution, city and country of all co-authors. 
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 Up to five keywords relevant to the content of your manuscript. This will enable us to 
identify the most suitable reviewers for your manuscript. 
 Word count, excluding title page, abstract, references, figures and tables. 
Manuscript format 
The manuscript must be submitted as a Word document. PDF is not accepted. 
The manuscript should be presented in the following order: 
 Title page. 
 Abstract, or a summary for case reports (Note: references should not be included in 
abstracts or summaries). 
 Main text separated under appropriate headings and subheadings using the following 
hierarchy: BOLD CAPS, bold lower case, Plain text, Italics. 
 Tables should be in Word format and placed in the main text where the table is first 
cited. 
 Tables must be cited in the main text in numerical order. 
 Acknowledgments, Competing Interests, Funding and all other required statements. 
Reference list. 
Images must be uploaded as separate files (view further details under the 
Figures/illustrations section). All images must be cited within the main text in 
numerical order and legends should be provided at the end of the manuscript. 
Appendices should be uploaded using the File Designation "Supplementary File" and 
cited in the main text. 
Please remove any hidden text headers or footers from your file before submission. 
Style 
Abbreviations and symbols must be standard. SI units should be used throughout, 
except for blood pressure values which should be reported in mm Hg. 
Whenever possible, drugs should be given their approved generic name. Where a 
proprietary (brand) name is used, it should begin with a capital letter. 
Acronyms should be used sparingly and fully explained when first used. 
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Figures/illustrations 
Images must be uploaded as separate files. All images must be cited within the main 
text in numerical order and legends should be provided at the end of the manuscript. 
Video: How to improve your graphs and tables >> 
Colour images and charges 
For certain journals, authors of unsolicited manuscripts that wish to publish colour 
figures in print will be charged a fee to cover the cost of printing. Refer to the specific 
journal’s instructions for authors for more information. 
Alternatively, authors are encouraged to supply colour illustrations for online 
publication and black and white versions for print publication. Colour publication 
online is offered at no charge, but the figure legend must not refer to the use of colours. 
Detailed guidance on figure preparation >> 
File types 
Figures should be submitted in TIFF or EPS format. JPEG files are acceptable in some 
cases. A minimum resolution of 300 dpi is required, except for line art which should be 
1200 dpi. Histograms should be presented in a simple, two-dimensional format, with no 
background grid. 
During submission, ensure that the figure files are labelled with the correct File 
Designation of “Mono Image” for black and white figures and “Colour Image” for 
colour figures. 
Figures are checked using automated quality control and if they are below the minimum 
standard you will be alerted and asked to resupply them. 
Please ensure that any specific patient/hospital details are removed or blacked out (e.g. 
X-rays, MRI scans, etc). Figures that use a black bar to obscure a patient’s identity are 
NOT accepted. 
Tables 
Tables should be in Word format and placed in the main text where the table is first 
cited. Tables must be cited in the main text in numerical order. Please note that tables 
embedded as Excel files within the manuscript are NOT accepted. Tables in Excel 
should be copied and pasted into the manuscript Word file. 
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Tables should be self-explanatory and the data they contain must not be duplicated in 
the text or figures. Any tables submitted that are longer/larger than 2 pages will be 
published as online only supplementary material. 
Video: How to improve your graphs and tables >> 
Multimedia files 
You may submit multimedia files to enhance your article. Video files are preferred in 
.WMF or .AVI formats, but can also be supplied as .FLV, .Mov, and .MP4. When 
submitting, please ensure you upload them using the File Designation "Supplementary 
File - Video". 
References 
Authors are responsible for the accuracy of cited references and these should be 
checked before the manuscript is submitted. 
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Appendix 2.2: Ethical Approval Letter I 
 
 
NRES Committees - 
North of Scotland 
Summerfield House 
 
  
12 December 2014 
 
 
Miss Kaye McKie  
Department of 
Clinical Psychology 
New Craig's Hospital 
 
 
Dear Miss McKie 
 
Study Title: Awareness of Cognitive Abilities in People with Parkinson’s disease 
 
REC reference: IRAS project ID: 14/NS/1080 160843 
 
The Research Ethics Committee reviewed the above application at the 
meeting held on 11 December 2014. 
 
Provisional opinion 
 
The Committee would be content to give a favourable ethical opinion of the 
research, subject to receiving a complete response to the request for further 
information set out below. 
 
Further information or clarification required 
 
1  The Committee wonder whether you have missed out an important step, 
namely, how the cognitive problems limit the ability to perceive problems 
and ask for clarification on this. 
 
2 A59 - please confirm whether it is possible to achieve the numbers required for 
the study. 
 
3  A13 - the Committee note that additional information regarding disease, 
duration of illness etc will be obtained prior to participation in the study. 
However, this is not clear in the Patient Information Sheet. Please include 
this in the Information Sheet. 
 
4  A13 – 4 - please provide details of who will carry out the motor 
examination and whether they are qualified to do so. 
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5 Please provide details of the recruitment process for control participants. 
 
6 Please clarify how carers will be recruited into the study. 
 
7  A17-2 - please confirm that participants presenting with depression or 
dementia will be excluded from the study as this is not clear. 
 
8  A-22 – the Committee note that ‘participation in the research might 
uncover a previously undiagnosed clinical problem’ and wonder whether 
the healthy volunteers will also be advised to speak to their GP. If so, 
then this will need to be made clear in the Healthy Volunteer Information 
Sheet and Consent Form. 
 
9  A13/53 – final paragraph - the Committee note that feedback will be 
provided to the clinical team however, this is not clear in the Information 
Sheet. Please include this in the Patient Information Sheet. 
 
10 A53 – please clarify the feedback process as this differs within the paperwork. 
 
Participant Information Sheet 
 
11  A35 - the Committee note that data already collected will be kept if a 
participant loses capacity. This will need to be made clear in the Patient 
Information Sheet. Please insert a sentence to reflect this. 
 
12 Please provide separate paperwork for the carers. 
 
Response Slip 
 
13 Please change ‘envelop’ to ‘envelope’. 
 
Poster 
 
14 Please amend the Poster so that it is relevant for the intended audience. 
 
15 Please amend the Poster using lay language. 
 
16 Please remove the bracket from ‘Stroke’ and insert it after ‘disorder’. 
 
Burden Interview Questionnaire 
 
17  The Committee ask whether it is possible to remove question 17 as it is not 
relevant to this study. 
 
Authority to consider your response and to confirm the Committee’s final 
opinion has been delegated to the Chair, Vice-Chair and Alternate Vice-
Chair. 
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When submitting a response to the Committee, the requested information 
should be electronically submitted from IRAS. A step-by-step guide on 
submitting your response to the REC provisional opinion is available on the 
HRA website using the following link: http://www.hra.nhs.uk/nhs-research-
ethics-committee-rec-submitting-response-provisional-opinion/ 
 
Please submit revised documentation where appropriate underlining or otherwise 
highlighting the changes which have been made and giving revised version 
numbers and dates. You do not have to make any changes to the REC 
application form unless you have been specifically requested to do so by the 
REC. 
 
The Committee will confirm the final ethical opinion within a maximum of 60 
days from the date of initial receipt of the application, excluding the time taken 
by you to respond fully to the above points. A response should be submitted by 
no later than 10 January 2015. 
 
Summary of the discussion at the meeting 
 
Social or scientific value; scientific design and conduct of the study 
 
On review of the application, the Committee wondered whether the researcher 
had missed out an important step, namely, how the cognitive problems limited 
the ability to perceive problems. 
 
A59 - the Committee wondered whether it would be possible for the researcher 
to achieve the numbers required for the study. 
 
A13 - the Committee noted that additional information regarding disease, 
duration of illness etc would be obtained prior to participation in the study. 
However, this was not made clear in the Patient Information Sheet. 
 
A13 – 4 - the Committee noted that a motor examination would be carried out. 
It was not clear from the paperwork who would carry this out and whether they 
were qualified to do so. 
 
Recruitment arrangements and access to health information, and fair participant   
selection 
 
The Committee felt that the control recruitment was vague and required clarification. 
 
The Committee asked for clarification on how carers would be recruited into the study. 
 
Favourable risk benefit ratio; anticipated benefit/risks for research participants 
(present   
and future) 
 
A-22 – the Committee noted that ‘participation in the research might 
uncover a previously undiagnosed clinical problem’ and wondered whether  
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the healthy volunteers would also be advised to speak to their GP. If so, 
then this would need to be made clear in the Healthy Volunteer Information 
Sheet and Consent Form. 
 
Care and protection of research participants; respect for potential and enrolled   
participants’ welfare and dignity 
 
A13/53 – final paragraph - the Committee noted that feedback would be 
provided to the clinical team however, this was not made clear in the 
Information Sheet. 
 
 
A53 - the Committee required clarification on whether participants would be 
given feedback at the end of the study as this differed within the paperwork. 
 
Participant Information Sheet  
A35 - the Committee noted that data already collected would be kept if a 
participant lost capacity. This would need to be made clear in the Patient 
Information Sheet. 
 
Informed consent process and the adequacy and completeness of participant   
information 
 
The Committee noted that there was no paperwork for the carers and asked 
that separate paperwork be provided which was relevant to them. 
 
Response Slip 
 
The researcher was asked to change ‘envelop’ to ‘envelope’. 
 
Poster 
 
The Committee felt that the Poster was only relevant to healthy volunteers and 
not for significant others or carers. The Poster would need to be changed to 
reflect the intended audience. 
 
The Poster should be written in lay language as in its present format was too technical. 
 
In the second paragraph, the bracket would need to be moved from ‘Stroke’ 
and inserted after ‘disorder’. 
 
Burden Interview Questionnaire 
 
The Committee noted that question 17 made reference to death, however the 
participant would still be alive. The Committee asked whether it was possible to 
remove this question as it was not relevant to this study. 
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
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Document 
 
Version 
 
Date 
 Copies of advertisement materials for research 
participants: Poster Advertisement 
 
2 
 
11 November 2014 
 
Covering letter on headed paper 
 
 18 November 2014 
 GP/consultant information sheets or letters: GP Letter 
 
2 
 
17 November 2014 
 IRAS Checklist XML: Checklist 24112014 
 
24 November 2014 
 Letter from Sponsor 
 
 4 November 2014 
 Letters of Invitation to Participant: Consent to Contact 
Form 
 
2 
 
17 November 2014 
 Non-validated questionnaire: Awareness Percentile Scale 
 
2 
 
17 November 2014 
 Non-validated questionnaire: Demographic Profile 
 
2 
 
17 November 2014 
 Participant Consent Form: PD Patient 
 
2 
 
17 November 2014 
 Participant Consent Form: HV Control 
 
2 
 
17 November 2014 
  
Document 
 
Version 
 
Date 
 Participant Information Sheet (PIS): PD Patient 
 
2 
 
17 November 2014 
 Participant Information Sheet (PIS): HV Control 
 
2 
 
17 November 2014 
 REC Application Form: REC Form 24112014 
 
24 November 2014 
 Referee's report or other scientific critique report: Proceed 
to Ethics Letter - University of Glasgow 
 
1 
 
26 September 2014 
 
Referee's report or other scientific critique report: 
CUSP Feedback 
 
 20 June 2014 
 
Research protocol or project proposal 
 
2 
 
17 October 2014 
 Summary CV for Chief Investigator (CI): Kaye McKie 
 
1 
 
15 October 2014 
 Summary CV for supervisor (student research): 
Hamish McLeod 
 
1 
 
12 August 2014 
 
Validated questionnaire: Awareness Questionnaire 
Patient Form 
 
1 
 
13 October 2014 
 
Validated questionnaire: RBANS 
 
1 
 
28 October 2014 
 Validated questionnaire: MDS-UPDRS part 3 
 
1 
 
13 October 2014 
 Validated questionnaire: HADS 
 
1 
 
13 October 2014 
 Validated questionnaire: Burden Interview 
 
1 
 
13 October 2014 
  
Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed 
on the attached sheet 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK. 
  
14/NS/1080 Please quote this number on all correspondence 
  
Yours sincerely 
 
 
Dr Alex Johnstone (Chair) 
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Copy to: Ms Frances Hines, NHS Highland 
 
 
NRES Committees - North of Scotland (2) 
 
Attendance at Committee meeting on 11 December 2014 
 
 
Committee Members: 
 
Name 
 
Profession 
 
Present 
 
Notes 
 Dr Alex Johnstone 
 
Chair & Senior Scientist in Human 
Nutrition 
 
Yes 
 
 
Dr Ruth Stephenson 
 
Vice Chair and Consultant in Anaesthesia Yes 
 
 
Mr Gary Cooper 
 
Lay Member - Alternate Vice Chair 
and Quality Assurance Manager 
 
Yes 
 
 
Mr Russell Brinklow 
 
Community Psychiatric Nurse 
 
Yes 
 
 
Dr Hanne Bruhn 
 
Lay Member - Research Fellow 
-Psychology 
 
Yes 
 
 
Dr Jennifer Caldwell 
 
Senior Lecturer in Occupational Therapy 
 
Yes 
 
 
Mrs Ann Conroy 
 
Retired Midwife 
 
Yes 
 
 
Dr Ian Fleming 
 
Research Fellow 
 
Yes 
 
 
Mrs Baljit Jagpal 
 
MRI Lead Superintendent 
 
Yes 
 
 
Dr Petr Kalous 
 
Consultant Neonatologist 
 
Yes 
 
 
Dr Kirsty Kiezebrink 
 
Lecturer 
 
No 
 
 
Mrs Kathryn McMullan 
 
Retired Clinical Pharmacist 
 
Yes 
 
 
Dr Jeremy Morse 
 
Manager of Clinical Skills 
 
Yes 
 
 
Mrs Sian Roughton 
 
Practice Educator Intensive Care 
Unit/Honorary Lecturer Aberdeen 
University 
 
No 
 
 
Mrs Fiona Watson 
 
Lay Member - Ex Company Director 
 
No 
 
 
Mrs Sophie Welch 
 
Coach Practitioner 
 
Yes 
 
 
 
Also in attendance: 
 
Name 
 
Position (or reason for attending) 
 Miss Karen Gauld 
 
Ethics Administrator 
 Mrs Carol Irvine 
 
Senior Ethics Co-ordinator 
  
Written comments received from: 
 
Name 
 
 Position 
 Mrs Sian Roughton 
 
Practice Educator Intensive Care 
Unit/Honorary Lecturer Aberdeen 
University 
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Appendix 2.3: Ethical Approval Letter II 
 
 
 
 
NRES Committees - 
North of Scotland 
Summerfield House 
  
23 December 2014 
 
 
Miss Kaye McKie  
Department of 
Clinical Psychology 
New Craig's Hospital 
 
 
Dear Miss McKie 
 
Study title: Awareness of Cognitive Abilities in People with Parkinson’s disease 
REC reference: IRAS project ID: 14/NS/1080 160843 
 
Thank you for your letter of 22 December 2014, responding to the 
Committee’s request for further information on the above research and 
submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by 
the Chair, Vice-Chair and Alternate Vice-Chair. 
  
We plan to publish your research summary wording for the above study on the 
HRA website, together with your contact details. Publication will be no earlier 
than three months from the date of this favourable opinion letter. The 
expectation is that this information will be published for all studies that receive 
an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact 
the REC Manager, Mrs Carol Irvine, nosres@nhs.net. Under very limited 
circumstances (e.g. for student research which has received an unfavourable 
opinion), it may be possible to grant an exemption to the publication of the 
study. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application form, 
protocol and supporting documentation as revised, subject to the conditions 
specified below. 
 
Conditions of the favourable opinion 
DClinPsy 2015 University of Glasgow 
Page | 120 
 
 
The favourable opinion is subject to the following conditions being met prior 
to the start of the study. 
 
 
Management permission or approval must be obtained from each host organisation 
prior to the   
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all 
NHS organisations involved in the study in accordance with NHS 
research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the 
Integrated Research Application System or at http://www.rdforum.nhs.uk. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) 
must be registered on a publically accessible database. This should be before the 
first participant is recruited but no later than 6 weeks after recruitment of the first 
participant. 
 
There is no requirement to separately notify the REC but you should do so at the 
earliest opportunity e.g. when submitting an amendment. We will audit the 
registration details as part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to request a deferral for study registration within the 
required timeframe, they should contact hra.studyregistration@nhs.net. The 
expectation is that all clinical trials will be registered, however, in exceptional 
circumstances non registration may be permissible with prior agreement from 
NRES. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular 
site (as applicable). 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject 
to management permission being obtained from the NHS/HSC R&D office prior 
to the start of the study (see "Conditions of the favourable opinion" below). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
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Document 
 
Version 
 
Date 
 Copies of advertisement materials for research 
participants: Poster Advertisement 
 
3 
 
15 December 2014 
 
Covering letter on headed paper 
 
 18 November 2014 
 Covering letter on headed paper: Response to 
Provisional Opinion 
 
 22 December 2014 
 
Covering letter on headed paper: Cover Letter 
 
3 
 
22 December 2014 
 GP/consultant information sheets or letters: GP Letter 
 
2 
 
17 November 2014 
 IRAS Checklist XML: Checklist 22122014 
 
22 December 2014 
 Document 
 
Version 
 
Date 
 Letter from Sponsor 
 
4 November 2014 
 Letters of invitation to participant: Consent to Contact Form 
 
3 
 
15 December 2014 
 Non-validated questionnaire: Demographic Profile 
 
2 
 
17 November 2014 
 Non-validated questionnaire: Awareness Percentile Scale 
 
2 
 
17 November 2014 
 Participant Consent Form 
 
3 
 
15 December 2014 
 Participant Consent Form: Healthy Volunteer 
 
3 
 
15 December 2014 
 Participant Consent Form: Spouse/Carer 
 
1 
 
15 December 2014 
 Participant Information Sheet (PIS) 
 
3 
 
15 December 2014 
 Participant Information Sheet (PIS): Healthy Volunteers 
 
3 
 
15 December 2014 
 Participant Information Sheet (PIS): Spouses/Carers 
 
1 
 
14 December 2014 
 REC Application Form: REC Form 22122014 
 
22 December 2014 
 Referee's report or other scientific critique report: Proceed 
to Ethics Letter - University of Glasgow 
 
1 
 
26 September 2014 
 
Referee's report or other scientific critique report: 
CUSP Feedback 
 
 20 June 2014 
 
Research protocol or project proposal 
 
2 
 
17 October 2014 
 Summary CV for Chief Investigator (CI): Kaye McKie 
 
1 
 
15 October 2014 
 Summary CV for supervisor (student research): 
Hamish McLeod 
 
1 
 
12 August 2014 
 
Validated questionnaire: RBANS 
 
1 
 
28 October 2014 
 Validated questionnaire: Awareness Questionnaire 
Patient Form 
 
1 
 
13 October 2014 
 
Validated questionnaire: MDS-UPDRS part 3 
 
1 
 
13 October 2014 
 Validated questionnaire: HADS 
 
1 
 
13 October 2014 
 Validated questionnaire: Zarit Caregiver Burden Inventory 
 
1 
 
15 December 2014 
  
Statement of compliance 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for 
researchers” gives detailed guidance on reporting requirements for  
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studies with a favourable opinion, including: 
 
 Notifying substantial 
amendments 
 Adding new sites and 
investigators 
 Notification of serious breaches 
of the protocol  Progress and 
safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is 
updated in the light of changes in reporting requirements or procedures. 
 
 
 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality 
service to all applicants and sponsors. You are invited to give your view of the 
service you have received and the application procedure. If you wish to make 
your views known please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/ 
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – 
see details at http://www.hra.nhs.uk/hra-training/ 
 
14/NS/1080 Please quote this number on all correspondence 
  
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
 
 
pp’d  
behalf 
of Dr 
Alex 
Johnst
one 
Chair 
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Appendix 2.4: Research and Development Approval Letter 
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Appendix 2.5: Participant Consent to Contact Form          
                                         
 
Study Title:  Awareness of Cognitive Abilities in People with Parkinson’s disease 
Date 
Dear  
 
I am writing to let you know about some research that is being completed by a final year 
Trainee Clinical Psychologist, called Kaye McKie, working within NHS Highland. 
Kaye is completing the research study as part of her doctoral degree at the University of 
Glasgow.  
 
Kaye is interested in investigating the impact Parkinson’s disease may have on people’s 
awareness of their cognitive abilities, such as, memory, attention and problem solving.  
 
The enclosed patient information sheet (version number 2; 11/11/2014) describes the 
study. It also explains what will happen if you decide to participate. Please take your 
time reading the information, feel free to discuss it with friends and family, the research 
team or myself. Contact detail are listed on the participant information sheet. 
 
If you decide that you would like to take part in this project, please let me know that 
you consent for your details to be passed to Kaye for her to contact you. You can do this 
by returning the attached response slip in the stamped addressed envelope provided or 
you can phone me and let me know. I will then pass your details to Kaye to make 
contact with you. Please return your slip within two weeks of the date at the top of the 
letter. If I do not hear from you by this time I will assume that you do not wish your 
details to be passed on, and do not wish to take part in the project. 
 
DClinPsy 2015 University of Glasgow 
Page | 126 
 
 
Please feel free to contact me if you have any questions and please be aware that I am 
independent of the research team. 
 
Address: Parkinson’s disease Department, Raigmore Hospital, Old Perth Road, 
Inverness, IV2 3UJ 
 
Tel: 01463 706378 
 
Thanks you for taking the time to read this letter. 
 
Yours sincerely, 
 
Dr Martin Wilson/ Ms Sharon Sutherland 
Parkinson’s disease Team 
 
 
Response Slip 
Study Title:  Awareness of Cognitive Abilities in People with Parkinson’s disease 
Please fill in this section and return using the self-addressed envelope if you consent for 
your contact details to be passed to Kaye McKie (Trainee Clinical Psychologist). 
 
Name:……………………………………………………………………………………
………… 
Address:…………………………………………………………………………………
……………………….……………………………………………………………………
……………………………..………………………………………………………… 
Telephone:……………………………………………………………………………… 
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Appendix 2.6: Participant Information Sheet         
                                         
 
Study Title:  Awareness of Cognitive Abilities in People with Parkinson’s disease. 
 
Participant Information Sheet 
Invitation to Participate in a Research Project   
We would like to invite you to take part in a research study. Before you decide, it is 
important that you understand why the research is being carried out and what is 
involved. Please take time to read the following information carefully and discuss it 
with others if you wish. Please contact us if there is anything that is not clear or if you 
would like any further information.      
 
Who is conducting the research?   
The research is being carried out by Kaye McKie (Trainee Clinical Psychologist) and 
Dr Hamish McLeod from the Institute of Health and Wellbeing of the University of 
Glasgow. The study is being undertaken as part of the fulfilment for an academic 
qualification (Doctorate in Clinical Psychology).   
 
What is the research about?  
This study is designed to investigate the impact of Parkinson’s disease on awareness of 
cognitive abilities, such as, memory, attention and problem solving. Awareness of our 
abilities is an important aspect of everyday life, as it provides us with the ability to 
recognise our limits, to judge risks and maintain relationships. Previous research has 
examined people with Parkinson’s disease level of awareness of motor symptoms, but 
there has been no research into their awareness of cognitive abilities. It is hoped this 
project will further our understanding of cognitive awareness in Parkinson’s disease and 
what this means for patients, carers and clinicians in a practical and functional sense.  
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Why have I been invited?   
You have been invited to take part in this study as you have a diagnosis of Parkinson’s 
disease and are over the age of 18 years.    
 
Do I have to take part?  
It is entirely up to you whether you take part or not. The research team will provide you 
with an information sheet and will give you at least 24 hours to decide whether you 
want to take part. If you still want to participate, then we will make arrangements to 
meet and you will be asked to sign a consent form to show you have agreed to take part 
in the study. If you decide to take part you are still free to withdraw at any time without 
giving a reason. In the (perhaps unlikely) event of a loss of capacity, the research team 
would retain personal data collected and continue to use it confidentially in connection 
with the purposes for which consent is being sought. A decision not to take part or a 
decision to withdraw from the study at any time will not affect the standard of care you 
receive now or in the future.  
 
What does taking part involve?   
If you decide to take part we will arrange a time convenient to you to come along and 
meet our researcher at your health centre. Taking part involves approximately 90 
minutes of assessment. This will include a variety of tasks such as completing 
questionnaires (one asking about mood, one asking about motor features of your 
condition and one asking questions about how you make decisions) and paper and pen 
style tasks (for example completing puzzles, memory and language tasks). You can 
have a break half way through testing and at any other time if required. With your 
permission additional information regarding severity of disease, duration of illness and 
current medications will be obtained from medical staff already involved your care, will 
be recorded.  
 
If you consent to the research team contacting a family member/carer, we will ask your 
family member or carer questions regarding your condition. This will consist of our 
researcher asking them to complete a short questionnaire, this will only take fifteen 
minutes.   
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What are the possible benefits of taking part?  
In general, research improves our knowledge of what people’s difficulties are and what 
we can do to help people overcome these and improve people’s lives. Your participation 
will help increase our knowledge of awareness of cognitive deficits and potentially 
improve treatment for others in the future.  
  
Are there any disadvantages or risks of taking part? 
There are no significant risks or disadvantages for taking part. You may feel a little 
tired, but there will be regular breaks during the assessment session to minimise this. 
Although we do not anticipate that participating in this study will cause you any 
distress, if this did happen we would help you to access appropriate support if needed. 
With your permission we will inform your GP that you are taking part in the study. 
 
Will my information be confidential?  
All the information you provide will be treated confidentially and the research 
questionnaires will only be identified by a code, not your name. The anonymised 
questionnaires will then be analysed by the research team. The consent forms and study 
data will be stored on University of Glasgow premises and will be accessible to 
researchers who are directly involved with the research.  
 
What happens to the information?  
Your identity and personal information will be completely confidential and known only 
to the researcher. The information obtained will be stored in a locked filing cabinet. The 
data are held in accordance with the Data Protection Act (1998), which means that we 
keep it safely and cannot reveal it to other people, without your permission. If we 
publish any findings from the study, this will be in the form where your results are 
combined with those of many other people and average scores are presented.  
 
What will happen to the results of the study?   
Within two weeks of completing the assessments, feedback of your results will be 
passed to the Parkinson’s disease team. You will then be able to collect your feedback 
at your next PD appointment. 
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On completion of the full research project the completed report will be submitted to the 
University of Glasgow as part fulfilment of the researcher’s Doctorate in Clinical 
Psychology degree. It is hope that the results will also be published in a medical journal 
and through other routes to ensure that the general public are also aware of the findings. 
You will not be identified in any report/publication arising from this study.  
   
Who is funding the research? 
This research is being funded by the University of Glasgow, Doctorate in Clinical 
Psychology.  
 
Who has reviewed the study? 
The study has been reviewed by the University of Glasgow to ensure that it meets 
standards of scientific conduct.  It has also been reviewed by the North of Scotland 
Research Ethics Committee (NOSREC) to ensure that it meets standards of ethical 
conduct.  
 Who can I contact for further information? 
If you require any further information or have any questions, please feel free to contact 
a member of the research team. Alternatively, you can speak to someone who is 
independent of the study who can answer questions or give advice.  
Name Role Contact 
Kaye McKie Trainee Clinical Psychologist 
NHS Highland 
Department of Psychology, New Craig’s 
Hospital, Drumossie Unit, Leachkin Road, 
Inverness, IV3 8NP 
Telephone: 01463 253697 
Dr Hamish McLeod Academic Supervisor 
University of Glasgow 
Academic Unit of Mental Health and 
Wellbeing, Gartnavel Royal Hospital, 1055 
Great Western Road, Glasgow, G12 0XH 
Telephone:   0141 211 3922     
Dr Jim Law Field Supervisor 
NHS Highland 
Department of Psychology, New Craig’s 
Hospital, Drumossie Unit, Leachkin Road, 
Inverness, IV3 8NP 
Telephone: 01463 253697 
Prof. Jon Evans Independent Contact 
University of Glasgow 
Academic Unit of Mental Health and 
Wellbeing, Gartnavel Royal Hospital, 1055 
Great Western Road, Glasgow, G12 0XH   
Telephone: 0141 211 3978    
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Appendix 2.7: Participant Consent Form          
 
 
                                         
Patient Identification Number: 
PARTICIPANT CONSENT FORM 
Awareness of Cognitive Abilities in People with Parkinson’s disease. 
Research Team: Researcher, Kaye McKie – Trainee Clinical Psychologist. Academic 
Supervisor, Dr Hamish McLeod - DClinPsy Programme Director. Local Field 
Supervisor, Dr Jim Law – Consultant Clinical Psychologist.      
           
           
   Please Initial the Box 
1. I confirm that I have read and understand the information sheet dated  
(11/11/2014; version number 2) for the above study.   
 
2. I have had the opportunity to consider the information provided, ask  
questions and had these answered satisfactorily.   
 
3. I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason, without my medical  
care or legal rights being affected.    
 
4. I understand that sections of my medical notes may be looked at  
by the research team where it is relevant to my taking part in the  
research. I give my permission for the research team to access my records. 
 
    
DClinPsy 2015 University of Glasgow 
Page | 132 
 
5. I give permission for a family member to be asked questions regarding 
my Parkinson’s disease and to complete a short questionnaire.   
 
 
6. I give permission for my GP to be informed that I am taking part in the  
current study. 
 
7. In the (perhaps unlikely) event of a loss of capacity, I consent to the 
     research  team retaining any personal data collected and allow them  
     to continue to use it confidentially in connection with the purposes for  
     which consent is being sought. 
 
 
8. I agree to take part in the above study.   
 
             
Participant signature: ......................................    Date: ………………………..  
 
 
Researcher signature: .....................................  Date: ………………………… 
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Appendix 2.8: Major Research Project Proposal        
 
Title: Awareness of Cognitive Deficits in Parkinson’s disease 
 
Abstract 
Background: ‘Anosognosia’ the awareness of ones deficits is an important aspect of 
functioning as it underpins the ability to recognise our limits. This function is 
commonly compromised in neurological diseases, such as Parkinson’s disease (PD). 
Although several studies have examined PD client’s level of awareness of motor 
symptoms there has been no research into PD patient’s awareness of cognitive deficits. 
Aims: This study aims to explore PD patient’s awareness of their cognitive deficits. In 
doing so, this study will also: explore perceived difference between clients level of 
awareness of cognitive deficit to that of their motor deficits and explore the relationship 
between clients level of awareness of cognitive deficit on caregiver burden. Methods: 
Participants with PD and a control group will predict their performance based on a 
percentile scale, prior to completing the global cognitive and global motor functioning 
assessment. Following task completion, participants will be asked to estimate their 
performance, therefore allowing for differences between self-rated and actual 
performances to be calculated. Practical Applications: The ability to recognize 
impairments and the capacity to self-monitor the impact on functioning is important in 
PD, as individual’s level of awareness has implications for level of their perceived risk 
in tasks of everyday living, carer burden, therapeutic and rehabilitation gains, It is hoped 
this project will further our understanding of awareness of cognitive deficit in PD and 
what this means for patients, carers and clinicians in a practical and functional sense.  
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Introduction 
The term anosognosia was introduced by Babinski (1914; cited in Klinowski & Paulsen, 
2013) to describe a lack of awareness/insight of one’s disease or deficit.  Awareness of 
our deficits is an important aspect of everyday life which provides us with the ability to 
recognise our limits (Williamson, Alcantar, Rothlind, Cahn-Weiner, Miller & Rosen, 
2010). However, this function is commonly compromised in neurological diseases, such 
as Parkinson’s disease (PD). Although several studies have examined PD clients level 
of awareness in terms of motor symptoms (Sitek, Sołtan, Wieczorek, Schinwelski, 
Robowsk, Reilmann, Guzińska, Harciarek, Krysa & Sławek, 2011), expressivity (Mikos, 
Springer, Nisenzon, Kellison, Fernandez, Okun & Bowers, 2009) and social deficits 
(Leritz, Loftis, Crucian, Friedman & Bowers, 2004) there has been no research into PD 
patients awareness of cognitive deficits. 
 
PD is the second most common degenerative neurological condition after Alzheimer’s 
disease. PD has a prevalence rate of 1/500, with an average age of onset around 60 
years. PD is initially characterized by motor symptoms such as rigidity and tremor of 
the limbs whilst at rest, bradykinesia and postural instability (Schapira, 2010). PD 
patients may also experience changes in non-motor symptoms, such as impairments in 
attention, memory, executive function (planning and mental flexibility), slowing of 
mental processing, delayed response time and visuospatial defects (Peto, Jenkinson, 
Fitzpatrick & Greenhail, 1995; Muslimovic, Post, Speelman & Schmand, 2005). It is 
estimated that 85% of PD patients exhibit deficits in cognitive functioning at various 
stages of disease progression (McNamara, 2011). 
 
Cognitive disturbances in PD can be as disabling as the motor symptoms of the disease, 
typically with attention, complex decision making and mental flexibility affected first 
(Schapira, 2010). However, these cognitive deficits are only recently attracting research 
attention. Correlational research has led to the suggestion that motor and cognitive 
impairments share a common pathophysiology and emerge together (Murakami, Owan, 
Mori, Fujita, Futamura, Sugimoto, Kobayawa, Kezuka, Midorikawa & Kawamura,  
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2013). Through the administration of the Montreal Cognitive Assessment (MoCA) and 
measure of general motor function, as measured by the Parts II and III of the Uniﬁed 
Parkinson’s disease Rating Scale (UPDRS) a signiﬁcant relationship between the degree 
of motor impairment and cognitive ability was shown (r= -0.45 Medium Effect).   
 
Awareness of deficit is a dimensional construct comprising of a level of explicit and 
implicit awareness of functioning, current situation, and of the disorder itself (Clare, 
2004). Explicit awareness is where the individual has the ability to verbally 
acknowledge their deficit and implicit awareness where the individual has the ability to 
accurately judge the impact of their cognitive deficit (Medin & McLeod, in 
preparation). However, even when the patient explicitly denies the presence of cognitive 
deficits, implicit awareness may be evident. Methods of measuring insight have 
primarily compared questionnaires that ask patients about their current abilities and 
compare these responses to the subjective perceptions of a close informant (Sherer, 
Bergloff, Boake, High & Levin, 1998).  Eslinger, Dennis, Moore, Antani, Hauck & 
Grossma (2005) proposed that an objective self-rating of awareness was needed in order 
to move away from the reliance of informant knowledge, which may pose a bias 
perspective. Eslinger et al (2005) devised a process of discrepancy scoring of objective 
self-ratings to indicate the patients perceptions of their own level of abilities and assess 
the two components of insight: self-awareness of the knowledge of ones abilities 
through pre-testing predictions, whereby the patient derives self-knowledge of abilities, 
reflection and previous life experience; self-monitoring of abilities through post-testing 
estimations, where the client judges their actual performance compared to their 
perceived performance. Williamson, Alcantar, Rothlind, Cahn-Weiner, Miller & Rosen 
(2010) devised an assessment strategy whereby the patient is asked to rate their 
performance on a percentile scale, represented as a bell shaped curve. This allows for a 
comparison between predicted and actual performance using the same percentile scale. 
However a potential concern for this measure is that it reflects overall estimation ability 
more than awareness of personal performance deficits. Due to the difficulties predicting 
percentile scores from poor estimation skills rather than poor insight, a further  
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comparison between two methods of assessing awareness of cognitive deficit will be 
completed (percentile vs questionnaire approach). 
 
The phenomenon of impaired awareness involves an inadequate evaluation of one’s 
impairments often underestimating the degree of their deficit, whereas their ability to 
rate others performing the same task remains intact (Clare, 2004). It has been suggested 
that several psychosocial factors, such as psychological denial, personal standards of 
success, compensatory strategies, and ageist preconceptions, might be important 
influences on reduced awareness (Ownsworth, Clare & Morris, 2006). In regards to 
dementia, Naylor & Clare (2008) state that reduced awareness may serve as a protective 
function against the threats to identity of self, by the onset and progression of the 
disease.  
 
Unawareness of deficit has significant impact on day to day functioning and affective 
state for the PD patient and their caregivers (Rosen, 2011). Due to PD being a 
degenerative disease the task of supporting and caring for the individual with PD 
usually falls to a spouse or family member. This can give rise to caregiver burden, the 
physical, mental, and socio-economic problems experienced by the caregivers of people 
with chronic diseases (Martinez-Martin, Forjaz, Frades-Payo, Rusinol, Fernandez-
Garcia, Benito-Leon, Arillo, Barbera, Sordo & Catalan, 2007). Predictors of caregiver 
burden in carers of PD patients include: time devoted to caring and strain deriving from 
the patient’s condition; disability and disease severity; psychological well-being of 
caregivers; clinical aspects of disease and patients’ mood (Martinez-Martin et al, 2007). 
 
Several studies have examined the impact of awareness of deficit of motor abilities on 
caregiver burden in carers of individuals with PD. Faison, Faria and Frank (1999) 
reported a positive correlation between level of care needed to perform activities of 
daily living and caregiver burden, r = 0.21 (small effect) indicating that increases in  
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ADL were associated with increases in caregiver burden.  De Bettigines, Mahurin & 
Pirozzolo (1990) found that level of insight was significantly correlated with the degree 
of caregiver burden, with higher levels of awareness of Independent Living Skills 
related to lower levels of caregiver burden. It would be interesting to examine 
awareness of cognitive deficit in PD in relation to caregiver burden as no previous 
research has been completed in this area. This would allow for real life implications of 
the impact of awareness and cognitive deficits to be better understand and enhance the 
literature. 
 
In conclusion, awareness of cognitive deficits in PD may have several real life 
implications on the individual with PD and their carer/spouse. Previous research has 
shown significant association between PD clients motor and cognitive abilities and 
significant relationship between awareness of motor abilities and caregiver burden. 
However, no research has examined the relationship between awareness of cognitive 
abilities and motor abilities, or the association between cognitive awareness and 
caregiver burden. In order to examine theses factor the development of methods for 
examining awareness of cognitive deficits in PD is required. 
 
Aims 
The aim of the proposed study is to analyse PD patient’s awareness of their cognitive 
deficits. It is hoped the results will further our understanding of awareness of cognitive 
deficit in PD and what this means for patients, carers and clinicians in a practical and 
functional sense. 
In doing so, this study will also:  
 Examine if there is a difference in magnitude between participants awareness of 
cognitive deficit to their awareness of motor deficits. 
 Examine the extent to which awareness of cognitive deficit impacts on caregiver 
burden.  
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Hypotheses 
 
1.  The ability to judge awareness varies within populations. As no previous research 
exists in relation to PD and cognitive awareness it will be interesting to examine 
whether people with PD will be less accurate at predicting and monitoring their 
cognitive abilities and performance compared to healthy control participants. 
Specifically, PD participants will overestimate their cognitive abilities, as measured 
by discrepancies between estimated and perceived performance on 
neuropsychological tasks, in comparison to the control group. As previous research 
stated the limits of percentile scales measures may be result from poor estimation 
skills rather than poor insight, a further comparison between the two methods of 
measuring awareness of deficit (percentile scale and questionnaire) will be 
completed for PD patients. 
 
2. Murakami et al.’s (2013) correlational study found a significant relationship 
between the PD participant’s degree of motor impairment and cognitive problems, 
suggesting that deficits in both areas occur simultaneously. However, the difference 
in awareness of motor and cognitive abilities has not been examined. Due to the 
salient feedback of motor deficits compared to the more discreet presentation of 
cognitive deficits in individuals with PD, it is predicted that self-ratings by PD 
participants of their awareness of cognitive abilities would be less accurate at 
predicting and monitoring performance, than self-ratings of their awareness of 
motor deficit. 
 
3. Based on Faison et al.’s (1999) significant positive correlational study of motor 
awareness and caregiver burden, it is predicted that greater unawareness of cognitive 
abilities will also correlate positively with carer burden. This will further our 
understanding of the progressive changes in cognitive ability in individuals with PD 
and its possible implications on caregiver burden. 
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Plan of Investigation  
Participant Recruitment Procedures  
Participants will be recruited from services at the Parkinson’s disease Unit in NHS 
Highland. Suitable participants will initially be informed of the study at routine 
outpatient clinics by a Consultant Geriatrician who specialises in Parkinson’s disease 
and/or a Specialist PD Nurse. Those who express interest will be provided with an 
information pack (which will include a participant information sheet, contact details of 
the researcher and a consent form). Potential participants will then be given an 
appointment or phone call with the researcher in order to answer any questions and 
provide further information. If informed consent is obtained, arrangements will be made 
for the testing session. 
 
Recruitment of Control Group (two options). 
1. In order to control for confounding variables such as demographic profiles it is 
planned that initial recruitment will be significant other/carers from the 
experimental participants. This would also allow for the comparison of 
awareness of deficit and caregiver burden. 
 
2. If the PD participant consents to the study but does not have a suitable carer/ or 
if the significant other does not give consent, the control group will consist of a 
population of older adults attending a local NHS physiotherapy service. 
 
In regards to carer burden, if the experimental participant has a significant other 
who consents to completing a single measure of caregiver burden, this will allow 
for an analysis of caregiver burden.    
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Exclusion Criteria 
 
  Due to increasing severity of motor control and physical disabilities as PD 
progresses, Individuals at Stage 5 of the Hoehn and Yahr (1967) rating scale 
(confinement to bed or wheelchair unless aided) will be excluded from the 
study.   
 Participants who are deemed by the clinical team to lack capacity to provide 
informed consent.  
 Participants should have no history of learning disabilities; no current 
psychiatric disorder (e.g. depression); Substance Misuse; or previous 
neurological conditions (e.g. Traumatic Brain Injury; Stroke). 
 
 
Measures  
Demographic information will be collected from all participants and a relative/carer 
(age, gender, marital status, relationship to the individual with PD (e.g. spouse), 
education and occupation). Additional information regarding severity of disease, 
duration of illness and current medications will be obtained from mental health staff 
involved in participants’ care and/or by case note review. 
 
List of standardised measures  
(Outline of all measures can be found in Major Research Project Paper -Chapter 
2,) 
 Test of Global Cognitive Functioning percentile scale based approach: 
Repeatable Battery for Assessment of Neuropsychological Status (RBANS) 
(Randolph, 1998).  
 Test of Global Cognitive Functioning questionnaire based assessment: The 
Awareness Questionnaire (Sherer, Bergloff, Boake, High & Levin, 1998). 
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 Test of Global Motor Functioning: The Movement Disorder Society (MDS)-
sponsored revision of the Uniﬁed Parkinson’s disease Rating Scale (MDS-
UPDRS) (Goetz, 2008).    
 Carer Burden: Zarit Caregiver Burden Inventory -ZCBI (Zarit, Reever & Bach-
Peterson, 1980).  
 Mood State: Hospital Anxiety & Depression Scale- HADS (Snaith and 
Zigmond, 1983). 
 
Assessing Awareness of Cognitive and Motor Deficit. 
In order to assess awareness of deficit, an assessment based on Medin and McLeod (in. 
prep) design will be used. This involves participants predicting their performance based 
on a percentile scale, prior to completing the cognitive assessment (RBANS) and motor 
functioning assessment (MDS-UPDRS). Following task completion, participants will be 
asked to estimate their performance on these assessments, therefore allowing for 
differences between self-rated and actual performances to be calculated. This analysis 
would assess the patient’s ability to predict and reflect on their test performance, error 
processing and ability to self-monitor. A further analysis will be conducted in order to 
examine whether there are differences in self- awareness between cognitive domains, it 
is proposed that this current study will compare predicated/estimated and actual scores 
on individual cognitive domain sub-scales. Due to the difficulties predicting percentile 
scores from poor estimation skills rather than poor insight, a further comparison 
between two methods of assessing awareness of cognitive deficit will be completed 
(percentile vs questionnaire approach). 
 
Design and Analysis 
This will be a cross-sectional study consisting of individuals with PD with varying 
degrees of severity of disease. To control for biases and potential influences a control 
group will be used. Participants in both the experimental and control conditions will be 
administered all standardised assessments and tests of cognitive and motor awareness. 
This study will comprise of a mixed method design: Between subject’s comparison of 
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PD and control participants objective self-ratings on pre-test predictions and post-test 
estimations of performance in tests of cognitive awareness. 
Within subjects comparison of PD participants awareness and monitoring of motor and 
cognitive abilities. Within subjects comparisons of discrepancies in awareness of 
abilities in individual cognitive domains for each PD participant. A further comparison 
of PD patient discrepancies in cognitive deficit will be correlated with perceived carer 
burden. 
  
Procedure 
Once recruitment and consent processes have been complete, the measures along with 
practice items will be administered in the following order:  
3. Demographic information (gathered from all participants). 
4. HADS (all participants) 
3.  The Awareness Questionnaire (PD Patients only) 
4. MD-UPDRS (PD Patients only) 
5. Zarit Caregiver Burden Inventory (carers only) 
BREAK 
6. Test of Global Cognitive Ability – RBANS (all participants) 
a. Pre-Test prediction of performance score 
b. Post-Test estimation of performance score 
BREAK 
7. Test of Global Motor Functioning – MDS-UPDRS – section 3 (PD Patients only) 
c. Pre-Test prediction of performance score 
d. Post-Test estimation of performance score 
      DEBRIEF 
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It is estimated that this process will last 90 minutes including rest breaks for PD Patients 
and 60 minutes for control group. The Zarit Caregiver Burden Inventory Carer 
assessment will take 15 minutes to administer. 
 
Sample Size* 
Due to the exploratory nature of this research no previous comparable studies exist from 
which an estimate of expected effect size could be obtained. A recent study which 
applied the discrepancy method of objective self-rating in examining awareness of 
cognitive abilities in people with schizophrenia, recruited 9 clinical participants and 22 
healthy controls (Medin & McLeod, in.prep) and found a statistically significant 
difference between the clinical and control group.  Effect sizes were around 0.54 for 
awareness of cognitive abilities, 0.62 for awareness of cognitive performance, and 0.67 
for monitoring of cognitive performance, as measured by between subject discrepancy 
data. 
 
It is reasonable to assume that the present study will have a similar effect size, 0.6.  It is 
estimated that 37 participants per group will be required to detect significant differences 
between groups with a significance level of alpha = 0.05, with a power of 0.8 (one 
tailed). 
*Please see MRP Addendum – Appendix 2.8 
 
Health and Safety Issues  
All Local and NHS health and safety procedures will be followed throughout the 
duration of this project. 
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Researcher safety – all participants will be seen in local NHS GP Surgery’s or in 
Hospital clinics. NHS Highland protocol will be adhered to and a panic alarm is situated 
in all clinical rooms. 
 
Participant safety – The testing session may be challenging for some adults with PD so 
frequent comfort breaks will be offered and participants can discontinue testing at any 
time without negative consequences.     
 
Ethical Issues (including where submissions will be made)  
Ethical applications will be submitted to the NHS Highland Research & Development 
Group and NHS ethics committee. 
 
Participants will be asked if they wish to participate in the study. The length of the 
testing session and purpose of the study will be explained to all participants and written 
consent will be obtained prior to testing. Care will be taken throughout the study to 
ensure that the participants are fully informed of the research procedures and have the 
opportunity to refuse or withdraw consent at any stage. All participants will be offered a 
debriefing at the end of the testing session. Following completion of the study 
information regarding the study outcomes will be sent to participants. 
 
All data sheets and database records will use a coding scheme to conceal the identity of 
participants.  All raw data will be stored in a locked filing cabinet and analysis of this 
data will be completed on an encrypted laptop.  
 
 
 
DClinPsy 2015 University of Glasgow 
Page | 145 
 
 
Financial Issues  
Materials - printer paper, access to an encrypted laptop, photocopier and printer will be 
required. 
Test materials: RBANS response sheets. 
Transport costs: Travel to and from base to clinical sites current petrol cost £0.24 per 
mile. (Invergorden Community Hospital – 40miles return trip and Raigmore Hospital – 
6miles return trip). 
 
Timetable 
 April 2014: Proposal submitted to University. 
 July 2014: Prepare ethics application.  
 September 2014: Application to NHS Highland Research & Development Group 
and ethical approval. 
 October 2014 – March 2015: Begin recruitment and data collection.   
 April – May 2015: Data analysis.  
 June - July 2015: Write up. 
 
Practical Applications 
 Cognitive impairment is common in PD and it is hoped this study will increase 
clinicians understanding of cognitive awareness in PD. Understanding the 
difference of perceived awareness of motor vs non-motor deficits in clients with 
PD. 
 Implications for the assessment and understanding of insight into cognitive 
deficits in people with Parkinson’s disease. 
 Implications in the medical and psychosocial management of Parkinsonian 
patients and useful for therapeutic intervention targeting PD cognitive decline at 
an earlier stage.  
 Implications on Caregiver Burden and carer well-being. 
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Appendix 2.9: Addendum to Major Research Project Proposal  
 
Amendment to Sample Size Calculation 
Through consultation with academic and field supervisors, it was decided that the initial 
sample size calculation based on Medin and McLeod (in.prep) was to be revised.  
As the current study used similar methodology as the Williamson et al (2010) study, 
assessed participants with a neurological condition and applied the same discrepancy 
method of objective self-rating when examining awareness of cognitive abilities, it was 
decided that a new sample size calculation would be conducted on the results of this 
study.  
 
 
 
